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Introduction: The dietary inflammatory index (DII) assesses an individual’s 
overall diet quality with regards to its inflammatory potential on a continuum from 
maximally anti-inflammatory (lower or healthier DII scores) to maximally pro-
inflammatory (higher or unhealthy DII scores). The DII measured at one point in time has 
been associated with cancer risk in previous studies; however, data are lacking regarding 
the change in DII over time and how these changes impact cancer risk. We assessed 
changes in the DII, and evaluated associations between cumulative history, and changes 
over time in dietary inflammatory potential, and risk of colorectal cancer (CRC) and 
breast cancer (BRCA). Methods: Study participants were women aged 50-79 years 
recruited from 1993-1998 into the Women’s Health Initiative (WHI) Observational Study 
(OS) and Dietary Modification Trial (DMT), and followed through September 30, 2010. 
The DII was calculated from repeated food frequency questionnaires (FFQ) data in the 
OS (n=76,671) at baseline and Year 3, and in the DMT (n=48,482) at up to 11 time 
points. Univariate generalized estimating equations were used to compare mean DII over 
time, adjusting for multiple comparisons. We calculated ten cumulative averages of DII, 
incrementally from baseline to Year 10, categorized each average into quintiles, and  
estimated hazard ratios (HR) and 95% confidence intervals (95%CI) for CRC, colon, 
rectal cancer and invasive BRCA incidence by DII quintiles in multivariable-adjusted
 
vi 
Cox regression models. We also derived patterns of changes in DII between baseline and 
Year 3; and calculated HR for CRC, colon, rectal, and breast cancer incidence including 
molecular and histologic BRCA subtypes, using multivariable-adjusted Cox regression 
models. Results: In the OS, mean DII decreased from -1.14 (±2.58) at baseline to -1.50 
(±2.60) at Year 3. In the DMT, DII decreased from -0.40 (±2.54) to its lowest point of -
1.70 (±2.63) at Year 3 in the intervention arm and from -0.38 (±2.55) to its lowest point 
of -1.04 (±2.60) at Year 3 in the control arm. These changes were influenced by BMI, 
education, and race/ethnicity. During an average 11.7 years, 1,240 cases of CRC and 
4,242 cases of BRCA were identified. HR for the association between high DII scores 
and CRC were consistently significantly elevated in the first seven years of follow up, for 
colon cancer with multivariable-adjusted HR ranging from 1.30 to 1.58 in quintile 3 vs. 1, 
while no significant associations were observed for rectal cancer. Compared to 
participants in the anti-inflammatory stable category, risk was increased in participants 
with a pro-inflammatory stable diet, for CRC (HR, 1.18; 95%CI, 0.99, 1.41), and for 
rectal cancer (HR, 1.53; 95%CI, 1.01, 2.32). HR revealed no significant association 
between changes in DII and risk of invasive BRCA or its subtypes. Conclusion: In this 
large prospective study of postmenopausal women, dietary inflammatory potential was 
relatively stable in OS participants, but decreased significantly over time in women 
enrolled in the DMT. DII changes were modified by BMI, education, and race/ethnicity. 
Long-term pro-inflammatory diets increased the risk of colon cancer, while shorter-term 
stable pro-inflammatory diets increased the risk of rectal cancer but not breast cancer or 
its subtypes. Lowering the inflammatory potential of diet could be a means for colon 
cancer, and potentially rectal cancer prevention in postmenopausal women. 
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1.1 Statement of the Problem 
Inflammation is a process central to carcinogenesis and other chronic diseases, 
and there is consistent evidence that diet modulates inflammation.
1-6
 Evidence from both 
observational and intervention studies show that chronic inflammation is associated with 
the development of many cancers including colorectal and breast cancers.
2,7-10
 Studies 
have  shown an association between chronic inflammatory conditions and subsequent 
malignant transformation in the inflammed tissue with some examples being 
inflammatory bowel disease and subsequent development of colorectal cancer,
11,12
 or 
Helicobacter pylori-related gastritis and gastric cancer.
8
 The etiology of inflammation 
varies and can be infectious, such as viruses or bacteria, or it may be a noninfectious 
irritant such as certain dietary factors.  
Many dietary factors are known to affect inflammation, through pro-inflammatory 
or anti-inflammatory mechanisms. A Western-style diet tends to be rich in pro-
inflammatory foods that are high in sugar (especially desserts and soft drinks), refined 
grains, red and processed meats, and fried foods that increase pro-inflammatory 
biomarkers such as C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis 
factor alpha (TNFα).
1-3,7,9,13,14




grains, legumes, nuts, olive oil and fish (e.g., Mediterranean-type diet) tend to be 
associated with reduced chronic inflammation.
3,4,15-17
  Likewise, East Asian populations, 
whose diets contain many anti-inflammatory constituents and are absent many of the pro-
inflammatory components in Western diets, have very low CRP levels.
18,19
 Specific 
components of the diet also have been shown to be associated with lower levels of 
inflammation; e.g., fruits and vegetables, omega-3 polyunsaturated fatty acids (PUFAs), 
fiber, moderate alcohol intake, vitamin E, vitamin C, β-carotene, and magnesium.
20
 
Dietary patterns are generally known to have a much wider safety margin with prudent 
consumption than do pharmaceuticals.
21,22
 Conceptually, dietary indices or patterns 
represent a broader picture of food and nutrient consumption, and may thus provide an 
approach to examining the relationship between diet and the risk of chronic diseases that 
may produce more intuitively appealing results that may be more predictive of disease 
risk as compared to the examination of individual foods or nutrients separately.
23-30
  
Despite the growing use of dietary pattern analysis, relatively few studies have 
investigated the stability of dietary patterns over time,
31-37
 and to the best of our 
knowledge, none has done so in relation to the inflammatory potential of diet. Dietary 
behavior is subject to change over time,
34,35
 and dietary behaviors mainly influence 
chronic disease outcomes when they persist for a longer period of time.
31
 Knowledge of 
the stability of dietary patterns over time could aid researchers in planning follow-up 
times right from study outset. The cost of maintaining large cohorts could be reduced if 
diet is proven to be stable over time. For example, reduced frequency of diet data 






Given the evidence that many dietary factors have either anti- or pro- 
inflammatory properties, and the idea that no nutrient is consumed alone but in 
conjunction with other nutrients and non-nutrient components of food, the dietary 




 The goal of the DII was to 
assess an individual’s diet on a continuum from maximally anti-inflammatory to 
maximally pro-inflammatory, thus providing a tool to measure the inflammatory potential 
of whole diets and their associations with markers of inflammation, and with the 
development of chronic diseases including cancer. 
1.2 Purpose and Objectives 
We proposed to utilize data from the Women’s Health Initiative (WHI) to 
describe longitudinal changes in the inflammatory potential of diet and evaluate the 
association of changes in the inflammatory potential of diet and risk of colorectal cancer 
and breast cancer in postmenopausal women. The WHI began in 1992, and enrolled a 
total of 161,808 women 50 to 79 years old, in 40 sites in the United States between 1993 
and 1998.
40
 We hypothesized that the inflammatory potential of diet changes over time 
and long-term pro-inflammatory diets or shorter-term changes towards pro-inflammatory 
diets, increase risk of colorectal cancer and of breast cancer. Our study aims were the 
following: 
Aim I: To investigate the stability of the inflammatory potential of diet over time. 
The WHI recruited a study population with a high racial and geographic diversity. 
We proposed to calculate the DII at all the eleven time points at which food frequency 




(OS) (baseline and year 3) and Dietary Modification Trial (DMT) (baseline, year 1 to 10). 
We expected that the inflammatory potential of diet would significantly change over time 
and be influenced by social, demographic and clinical factors. The main study questions 
for aim #1 included the following:  
1. Are there changes in dietary inflammatory potential over time?  
2. If there are any significant changes, how do demographic and lifestyle factors such as 
body mass index (BMI), education, and race/ethnicity impact such changes? 
3. What social, demographic and clinical factors predict change in DII? 
4. How does the change in the inflammatory potential of diet in an intervention setting 
differ from that in an observational setting? 
Aim II: To evaluate the association between changes in the inflammatory potential 
of diet over time and risk of colorectal cancer. 
In specific aim #2, we evaluated the association between the inflammatory 
potential of diet and risk of colorectal cancer with the hypothesis that a long-term pro-
inflammatory diet increases colorectal cancer risk. The dietary inflammatory potential 
assessed at baseline only has been linked to colorectal cancer risk (Tabung FK, Steck, 
SE, Ma Y, et al, unpublished data, 2014), however, data is lacking on the impact of 
longitudinal changes in dietary inflammatory potential on colorectal cancer development. 
Utilizing the DII to evaluate the role of long term dietary inflammatory potential on the 
risk of colorectal cancer is therefore warranted. The main questions for this aim included 




1. How does long-term cumulative history of dietary inflammatory potential affect 
colorectal cancer risk? 
2. How do shorter-term changes in patterns of the inflammatory potential of diet over 
time affect risk of colorectal cancer? 
3. Do risk estimates differ by anatomic subsite (colon, rectum) both for cumulative 
history and patterns of change in the dietary inflammatory potential? 
Aim III: To investigate the association between changes in the inflammatory 
potential of diet over time and risk of breast cancer in postmenopausal women. 
In specific aim #3, we investigated the association between the inflammatory 
potential of diet and breast cancer risk in postmenopausal women, with the hypothesis 
that a long-term pro-inflammatory diet increases breast cancer risk. The association 
between dietary patterns and breast cancer risk is inconsistent,
41-45
 with findings from 
three large cohort studies not supporting an association between dietary patterns and 
breast cancer risk.
44,46,47
 Given the central role of chronic inflammation in the 
carcinogenesis process,
48-50
 and the modulation of inflammation by some dietary 
patterns,
3,4,14,16,17,48
 an assessment of the dietary inflammatory potential at multiple time 
points may be more predictive of breast cancer risk. The main questions for this aim 
included the following:  
1. How does long-term cumulative history of dietary inflammatory potential affect 
breast cancer risk? 
2. How do shorter-term changes in patterns of the inflammatory potential of diet over 




3. Do risk estimates differ by molecular or histologic subtype of breast cancer for 
patterns of change in the dietary inflammatory potential? 
1.3 Significance/relevance of the dissertation research 
This dissertation addressed an important area of cancer research which includes 
the role of total diet with respect to its inflammatory potential, in relation to risk of cancer 
in a large, well-characterized cohort (the WHI) with adequate number of outcomes 
providing ample power to detect significant associations. Given that the DII has been 
shown to be associated with inflammatory biomarkers (Tabung FK, Steck SE, Zhang J, 
Ma Y, et al., unpublished data, 2014) and with colorectal cancer incidence (Tabung FK, 
Steck SE, Ma Y, et al., unpublished data, 2014) in this study population, the examination 
of DII changes over time and cancer endpoints is a crucial next step in evaluating the DII 
as a tool for cancer prevention.  
1.3.1 High public health and clinical impact 
This study is innovative in that this is the first time that repeated measures of the 
DII are being used to evaluate the association between changes in the dietary 
inflammatory potential over time and cancer endpoints. The study will likely have a large 
public health impact by strengthening the evidence for a new tool assessing the long-term 
overall quality of diet and providing support for its use in other studies of diet and cancer.  
Patients at risk of inflammation-related conditions such as osteoporosis, obesity, 
cardiovascular disease, and diabetes, may also be at risk of cancer.
51,52
 Therefore a 
reduction in the inflammatory potential of the diet among patients with these conditions 
may improve overall health and reduce their cancer risk. The diagnosis of most of these 




lifestyle changes including diet changes to improve their survival experience.
53,54
 Health 
professionals armed with the knowledge of the inflammatory potential of diets may be 
able to impart sound nutritional guidance that improves the overall health of patients with 
inflammation-related chronic diseases.  
1.3.2 The role of the inflammatory potential of whole diets and dietary patterns on 
cancer risk is largely unknown 
 Studies of individual foods and nutrients may be inadequate to elucidate the 
overall role of long term diets and dietary patterns on the risk of degenerative diseases 
including colorectal cancer and breast cancer. The role of diet in the risk of these cancers 
is of great interest as a potentially modifiable risk factor given that most risk factors for 
breast cancer are not generally modifiable. Many epidemiological studies of the 
association between single dietary factors and colorectal and breast cancers have not 
yielded consistent conclusive evidence except for overweight/obesity (increases risk of 
postmenopausal breast cancer and colorectal cancer),
55-62
 regular alcohol 
consumption,
55,63,64
 and red meat intake.
65-70
  
In a dietary guidelines adherence study, Harnack and colleagues found evidence 
to suggest that adherence to the cluster of dietary behaviors included in the Dietary 
Guidelines for Americans is associated with a lower risk of cancers including colon and 
breast cancers,
71
 while McCullough and colleagues found that following cancer 
prevention guidelines, reduces risk of cancer, cardiovascular disease, and all-cause 
mortality.
72
 This evidence supports the idea that studies of the oncogenic role of whole 
diets and not individual nutrients may be more appropriate for population-based cancer 
prevention efforts. As further evidence, the impact of total caloric intake, energy balance, 
and weight gain on the risk of breast
73,74
 and colorectal cancer
75,76








1.4 Study Outline 
Chapter 1 of this dissertation introduces the problem by first establishing the link 
between dietary patterns and chronic inflammation, and the link between inflammation 
and cancer, with the ultimate aim to elucidate the role of dietary inflammatory potential 
in cancer development. Aims have been stated and their specific significance described, 
in addition to the overall significance of the dissertation. Chapter 2 presents a detailed 
background to the aims in an extensive review of the literature. It describes the relation 
between diet and inflammation and inflammation and cancer, including possible 
mechanisms of action. Selected theoretically-derived diet quality indices and their 
relation to inflammation are described, including empirical methods of evaluating dietary 
patterns and some statistical approaches to analyzing repeated dietary exposures with 
dichotomous outcomes. Chapter 2 ends with a detailed review of possible risk factors for 
colorectal cancer and breast cancer. In chapter 3, we describe the methods used to 
achieve each of the three aims, including a detailed description of the DII. Results for 
each of the three aims are presented separately in chapters 4, 5 and 6, as standalone 









2.1 Chronic inflammation and cancer 
2.1.1 Overview 
In the mid nineteen century, Virchow theorized that the lymphoreticular infiltrate 
at sites of chronic inflammation may establish the setting in which cells grow 
abnormally.
7,77
 A more contemporary version of Virchow’s hypothesis is that the 
inflammatory processes induced by chronic injury contribute to the multistage 
development of cancer and that the inflammation, rather than the specific cause of the 
injury, account for subsequent carcinogenicity.
78
 Inflammation is a crucial function of the 
innate immune system with acute inflammation being a self-limiting process that protects 
against pathogens and initiates specific immunity, however, acute inflammation does not 
always resolve.
79
 Many of the diseases of middle and old age may be driven, at least in 
part, by chronic and often subclinical inflammation.
79
 Several lines of evidence, including 
general or cell-specific gene inactivation and population-based studies, are consistent 
with the view that inflammation plays an important role in cancer causation and/or 
progression. As Balkwill et al. indicated,
79
 the links between chronic inflammation and 
cancer are reinforced by several concepts including the following: i) many cancers arise 




immune cells that mediate chronic inflammation are found in cancers and promote tumor 
growth, iii) cancers produce  chemical mediators that regulate inflammation, iv) 
experimental cancers have been inhibited by the inhibition of inflammatory mediators, v) 
susceptibility to, and severity of cancer is altered by the variation of inflammatory genes, 




More recently, the role of inflammation in cancer development was highlighted 
by Brucher and Jamall when they proposed a new paradigm for the epistemology of the 
origin of cancer.
80
 They stressed that less than 10% of all cancers are hereditary, and 
departed from the widely held concept that cancer originates from somatic mutations and 
an inhibition of growth suppression, followed by cell proliferation and metastasis.
80
 
According to their new paradigm, the origin of cancer follows a sequence of events 
beginning with 1) a pathogenic stimulus which can be biologic or nonbiologic (including 
diet), 2) followed by chronic inflammation, 3) from which fibrosis develops, with 
associated changes in the cellular microenvironment if the inflammation does not resolve, 
4) a pre-cancerous niche then develops which triggers  5) a chronic stress escape strategy 
6) that transforms a normal cell to a cancer cell if the chronic stress does not resolve.
80
 If 
this hypothesis is true, then intervening to prevent or reduce chronic inflammation that 
may be triggered by potentially modifiable risk factors such as diet, may present an 
excellent opportunity for the primary prevention of cancers. 
2.1.2 Chronic inflammation and colorectal cancer 
Several lines of evidence suggest that colorectal neoplasia may arise from colonic 
areas with chronic low grade subclinical inflammation.
81,82




diseases, such as ulcerative colitis and Crohn’s disease have been associated with 
increased risk of colon cancer.
12
 Moreover, several studies have shown a reduced risk of 
colon cancer with use of aspirin or other anti-inflammatory agents.
79,83,84
 Patients with 
long-standing ulcerative colitis and Crohn's disease have an increased risk of developing 
colorectal cancer and patients with Crohn's disease in the small intestines are at increased 
risk of small bowel adenocarcinoma.
82,85
 Inflammatory bowel disease-related colorectal 
cancer is the result of a process which is believed to begin from no dysplasia, progressing 
to indefinite dysplasia, low-grade dysplasia, high-grade dysplasia and finally to invasive 
adenocarcinoma.
86
 This is also called the adenoma-carcinoma sequence, although 
colorectal cancer can arise without proceeding through each of these steps.
12,86,87
 
Several prospective studies have supported the hypothesis that inflammation is a 
risk factor for the development of colon cancer.
88-91
 A study analyzing change in C-
reactive protein (CRP) and serum amyloid A (SAA) over time in relation to risk of 
colorectal cancer using data from the WHI observational study, observed an increased 
risk of colon cancer among women in the highest quintile of CRP change compared to 
those in the lowest quintile (OR; 1.37, 95%CI; 0.95, 1.97), p-trend = 0.04) but no 
association with SAA.
89
 Women with elevated concentrations of both CRP and SAA had 
an increased risk of colon cancer (OR; 1.50, 95%CI; 1.12–2.00) compared to those with 
low concentrations.
89
  The study observed no positive associations with rectal cancer and 
weaker associations for colorectal cancer overall. Furthermore, temporal changes in 
biomarkers more than 3 years did not predict risk.
89
 An examination of the association of 
CRP levels with colorectal cancer incidence in a nested case-control study within the 




colon cancer incidence for men with the highest concentration of CRP (OR, 2.9; 95%CI, 
1.4, 6.0) compared to men with the lowest concentration, with the association being 
stronger among lean individuals than in heavier individuals.
91
 Another nested case-
control study found that the odds of developing colorectal cancer increased with higher 
concentrations of CRP, such that persons in the highest quartile of CRP had a 2-fold 
increased risk of colorectal cancer compared with persons in the lowest quartile (OR, 




In summary, whether levels of inflammatory biomarkers are elevated before 
biological onset of colorectal cancer, or indeed whether inflammatory biomarkers are risk 
factors for the de novo development of colorectal cancer, are questions that relatively few 
of the prospective studies have tried to address.
92
 The presence of malignant disease may 
itself affect concentrations of circulating inflammatory biomarkers from retrospective 
case-control studies or from cohort studies where case diagnosis close in time to blood 
draw might reflect tumor marker status rather than true risk assessment. Whether 
circulating concentration of inflammatory biomarkers truly reflects colonic inflammation 
and/or translates into biological activity is unclear. This emphasizes the need for more 
research to explore the association of inflammatory biomarkers with colonic 
inflammation. As cancer is a relatively rare disease, small numbers of colorectal cancer 
cases and lack of power pose problems in many prospective epidemiologic studies. 
2.1.3 Inflammation and breast cancer 
Studies focusing on the tumor microenvironment have demonstrated that 




cancer, including breast cancer.
93
 The cytokines interleukin-6 (IL-6), IL-1β and tumor 
necrosis factor alpha (TNFα), have been found to be associated with breast cancer 
progression.
94-96
 An analysis of data from the Health, Eating, Activity, and Lifestyle 
Study on the relationship between circulating markers of inflammation (CRP and SAA) 
and breast cancer survival found that SAA and CRP significantly predicted long-term 
survival in breast cancer patients, independent of race, tumor stage, and BMI.
93
 In 
contrast, a meta-analysis of prospective studies of the association between circulating 
CRP and IL-6 and the development of specific cancers, found no association with an 
increased breast cancer risk.
97
 In a Swedish study of 2,577,565 women to examine 
possible associations between mastitis and subsequent risk of breast cancer, the 
investigators found that breast cancer risk was slightly elevated in women with a history 
of mastitis (incidence rate ratio: 1.23, 95%CI, 1.02-1.49).
98
 The absence of a correlation 
between laterality of lesions (i.e., the breast with mastitis was not always the breast with 
cancer), however, did not support a causal association between inflammation (mastitis) 
and the development of breast cancer in the study.
98
 
An assessment of the association for use of aspirin, other non-steroidal anti-
inflammatory drugs (NSAIDs), and acetaminophen with breast cancer risk among breast 
cancer-free (at baseline) premenopausal women in the Nurse’s Health Study II, found 
that regular use of aspirin (≥ 2 times/ week) was not significantly associated with breast 
cancer risk (RR, 1.07; 95%CI, 0.89-1.29). Additionally, non-aspirin NSAIDs or 
acetaminophen were not consistently associated with breast cancer risk in premenopausal 
women, and results did not vary by frequency (days per week), dose (tablets per week), 
duration of use or estrogen and progesterone receptor status of the tumor.
99




study, the use of ibuprofen or acetaminophen was not associated with breast cancer 
risk.
100
 In contrast, a case-control study to investigate the association of adult lifetime 
aspirin intake with breast cancer risk, found evidence that aspirin use throughout a 
woman's life may confer some benefit (adjusted OR 0.80, 95% CI: 0.68-0.94), comparing 
aspirin users to non-users, and a large cohort study of postmenopausal women followed 
for more than 6 years, found a trend of decreasing risk of incident breast cancer with 
increasing frequency of aspirin use (Ptrend = 0.001).
101
 The multivariate-adjusted RR of 
breast cancer was 0.71 (95% CI 0.58-0.87) for women who reported using aspirin six or 
more times per week compared with women who reported no use. No association was 
found between non-aspirin NSAID use and incident breast cancer.
101
 
In summary, while most of the evidence is consistent that chronic inflammation 
increases the risk of breast cancer recurrence or survival, the evidence has been less 
consistent for the association between chronic inflammation and breast cancer incidence. 
Most of the research on the association between chronic inflammation and breast cancer 
incidence has been through the intermediacy of anti-inflammatory drugs such as aspirin 
and non-aspirin NSAIDs and is inconsistent.  
Many sites of chronic uncontrolled low grade inflammation many exist in the 
body at the same time and most of the biomarkers of inflammation usually employed in 
epidemiologic studies are non-specific. This may explain the weak associations or lack 
thereof, between biomarkers of inflammation and the development of breast cancer or 
colorectal cancer in some studies. Thus, biomarkers of inflammation are associated with 




markers correlate with breast or colorectal inflammation respectively. Moreover, CRP 
(used in most of the studies) is a non-specific marker of inflammation. 
2.1.4 Biologic plausibility and mechanisms for inflammation and cancer 
The chronic inflammatory response represents a fine balance between active 
inflammation, repair, and destruction that occurs in response to a persistent stimulus over 
a prolonged period of time.
9
 Activation of leukocytes in response to such an ongoing 
stimulus leads to the production of cytokines, and reactive oxygen species (ROS), 
resulting in accumulated tissue destruction and subsequent attempts at healing via 
remodeling, angiogenesis, and connective tissue replacement.
9,102
 A wide variety of 
chronic inflammatory diseases are associated with cancer.
78
 Indeed, chronic inflammation 
orchestrates a tumor-supporting microenvironment that is an indispensable participant in 
the neoplastic process. Important components in this linkage are the cytokines produced 
by activated innate immune cells that stimulate tumor growth and progression.
103
 
Supporting evidence for the inflammation-cancer link comes from studies 
showing that diverse infections and mechanistic agents trigger the inflammation 
associated with human cancer. These links have been confirmed especially in terms of 
colon cancer (colitis),
8,12
 gastric cancer and MALT
1
 lymphoma (Helicobacter pylori 
infection),
8,104,105
 liver cancer (cholangitis and hepatitis virus B and C),
106,107
 and 
Kaposi’s Sarcoma (Human Herpes Virus 8 infection).
108
 Chronic inflammation appears to 
predispose to the development of colon cancer in the setting of inflammatory bowel 
disease,
79,109,110
 following an “inflammation-dysplasia-carcinoma" model.
111
 
                                                          
1




A second line of evidence for the biologic plausibility of the association between 
inflammation and cancer relates to the increased expression of inflammatory mediators 
that occurs during tumor development. Balkwill and Mantovani demonstrated that acute 
inflammation triggered by the exogenous administration of inflammatory biomarkers in 
murine models promotes malignancy and metastasis under controlled conditions.
7
 The 
link between inflammation and cancer is further supported by evidence from studies 
showing a positive association between higher concentrations of inflammatory 
biomarkers and increased risk of colon cancer.
89,112,113
  
The third and complementary line of evidence is the fact that NSAIDs, which 
inhibit COX-2 activity and tumor development in many experimental and clinical 
settings, are inversely associated with certain cancers in epidemiological studies.
78,114
 
Inflammatory cytokines induce the production of inflammatory enzymes such as the 
cyclo-oxygenases (COX). The expression of COX-2 and lipid mediators of inflammation 
increases during the multistage progression of neoplastic conditions.
115
 Observational 
studies and human intervention trials have also indicated that the regular administration 
of NSAIDs confers a 30–50% reduction in colorectal cancer risk or adenoma 
recurrence.
116,117
 We previously found an association between the consumption of highly 
pro-inflammatory diets and higher concentrations of inflammatory biomarkers including 
IL-6, hs-CRP, TNFα-R2 and an overall inflammatory biomarker score derived from a 
combination of these biomarkers (Tabung FK, Steck SE, Zhang J, et al, unpublished data, 
2014). In another study to evaluate the association between the inflammatory potential of 




participants consuming a highly pro-inflammatory diet (Tabung FK, Steck SE, Ma Y, et 
al., unpublished data, 2014).  
2.2 Dietary patterns and chronic inflammation 
2.2.1 An overview of opportunities and challenges 
The traditional approach to studying the relation between diet and disease has 
been to focus on the effects of specific nutrients, foods or food groups but people 
consume a wide variety of diets, not isolated nutrients or foods. Additionally, people eat 
diets in specific patterns that are influenced by the environmental conditions of living, 
religious opinions, personal preferences, food availability, economical status and many 
other cultural factors. Dietary pattern research thus offers a more comprehensive 
approach to the investigation of diet-disease associations. Nutritional epidemiologists cite 
several reasons for preferring the dietary pattern approach over the traditional nutrient-
based approach, including the following:
25-27,118-121
  1) nutrient-based research does not 
consider the complex interactions among nutrients in metabolic reactions; nutrients may 
interact with each other and influence their bioavailability and absorption; 2) increased 
consumption of one food (i.e., red meat and related products) may be associated with 
reduced consumption of other foods (i.e., fruit and vegetables) since the total energy 
intake of individuals should remain stable; 3) many nutrients are highly correlated and 
studying their separate effects is hampered by collinearity; 4) the effects of single 
nutrients may be too small to detect while the synergistic and larger effect of nutrients 
with similar effects may be more easily detected in dietary patterns; 5) analysis of 
individual nutrients may be confounded by dietary patterns and 6) the success of “whole 




and the Lyon Diet Heart Study.
122-124
 The two main approaches for deriving dietary 
patterns are the a priori or index-based approach and the a posteriori or data-driven 
approach. These approaches are reviewed in more detail in sections 2.2.2 and 2.2.3.  
The index-based approach is intuitively appealing, analytically simple to 
compute, and easily reproducible and comparable across different studies. Scores that 
dichotomize components do not account for the full range of foods consumed, while 
scores that award points for a range of intakes consider variability in food intake but not 
the amounts at the extremes of component intake distributions.
25,28
 Subjectivity may be 
introduced during index construction in the selection of foods for inclusion. Also, the 
addition of equally weighted components implies that each component is additively 
related to health and equally important.
25
 
Data-driven methods (e.g., factor analysis, cluster analysis) have shown some 
level of reproducibility across populations.
125,126
 Patterns allow for biologic interactions 
and can thus be the starting point for modeling different types of interactions among 
foods.
25
 While factor analysis describes the variation in food intake in the population 
based on correlations among dietary factors as a continuous variable, cluster analysis 
separates subjects into mutually exclusive groups based on dietary intake as a categorical 
variable.
25
 Generally, there is limited data on the reproducibility and validity of data-
driven methods, though reproducibility in different populations can never be expected to 
be exact due to the data-driven nature of the approach. Subjectivity is introduced at 
various points including grouping of dietary items, treatment of input items (e.g., whether 








Both index-based and data-driven approaches to dietary pattern analysis thus 
characterize total diet and overcome most of the limitations of single-nutrient research, 
and analysis results are more meaningful, interpretable and associated with health 
outcomes.  
Regarding the relation of dietary pattern and inflammation, Western-style eating 
patterns are characterized by frequent intake of energy-dense food and beverage portions 
delivering an excess of readily available carbohydrates and fats, and few other nutrients. 
This eating pattern, combined with a sedentary lifestyle, results in weight gain, but it is 
also associated with increased production of reactive oxygen species (ROS).
127
 As people 
gain weight and become overweight and obese, CRP, along with other inflammatory 
mediators, also increases.
128,129
 ROS, also known as free radicals, lead to an acute 
oxidative imbalance, resulting in oxidative stress. Oxidative stress “turns on” genes that 
control the production of cytokines and other proteins (biomarkers) involved in 
inflammation.
130,131
 Since eating is not a one-time activity, but rather an activity that we 
repeat meal after meal and day after day, the diet then becomes a central point of 
negotiation for oxidative and inflammatory balance.  
2.2.2 Comparison of selected diet quality indices and their association with 
inflammation 
This section reviews the strengths and limitations of three diet quality indices 




(DASH), and the Mediterranean dietary pattern), comparing each of them to the dietary 
inflammatory index (DII) in terms of their ability to modulate inflammation. The 
discussion is undertaken from both the perspective of the theoretical underpinnings of the 
respective strategies for the development of each index, as well as the statistical 
considerations /limitations of each index.  
2.2.2.a Brief overview of the dietary inflammatory index (DII) 




 of the DII have been described 
elsewhere. Briefly, an extensive literature search was performed to obtain peer-reviewed 
journal articles that examined the association between six inflammatory biomarkers (IL-
1, IL-4, IL-6, IL-10, TNFα, and CRP) and 45 specific foods and nutrients (components 
of the DII).  Scores were derived and standardized to a representative global diet database 
constructed based on 11 datasets from diverse populations in different parts of the world.  
Overall DII scores for each individual represent the sum of each of the DII components in 
relation to the comparison database.
38
 The DII score characterizes an individual’s diet on 
a continuum from maximally anti-inflammatory to maximally pro-inflammatory, with a 
higher DII score indicating a more pro-inflammatory diet and a lower DII score 
indicating a more anti-inflammatory diet. A more detailed description of the DII can be 
found in chapter 3, section 3.5. 
2.2.2.b Healthy Eating Index (HEI) 
The HEI was developed based on a 10-component system of five food groups 
(grains, vegetables, fruits, milk and meat), four nutrients (percent energy from total fat, 
percent energy from saturated fat, cholesterol intake, sodium intake), and a measure of 




total possible index score is 100. A score of 0 indicates non-compliance with 
recommended amounts or ranges while a score of 10 indicates intakes closest to 
recommended amounts or ranges.
132
 
Though the HEI was developed to measure adherence to the Dietary Guidelines 
for Americans (DGA) and the Food Guide Pyramid, some studies have investigated the 
association of the HEI and inflammation with the main finding being that the HEI does 
not significantly predict biomarkers of systemic inflammation such as CRP, SAA and IL-
6,
133-135
 and has equally performed poorly in predicting chronic disease risk.
136
 The HEI’s 
low predictive ability (or lack thereof) for chronic systemic inflammation and chronic 
disease may be due to its inability to distinguish between the form of carbohydrate, 
saturated and unsaturated fats, or protein sources (e.g., processed meats versus fish). 
These limitations were addressed in the development of an alternate HEI (aHEI). A study 
comparing the disease predictive ability of the HEI and aHEI found that the aHEI 
significantly predicted risk of cardiovascular disease (CVD) but both indices failed to 
predict cancer risk.
136,137
 In a study to assess the association between several diet-quality 
indices and plasma concentrations of biomarkers of inflammation and endothelial 




An updated version of the HEI (HEI-2010) was published in February 2013, to 
reflect the 2010 updated DGA (DGA-2010).
138
 In accordance with the DGA-2010, the 
HEI-2010 allows for flexibility in food choices. The advantage of this is that lack of any 
one commodity does not prevent anyone from having a perfect HEI-2010 score. 




vegan diets to be scored. Similar to the aHEI, the HEI-2010 now distinguishes quality 
within food groups and acknowledges the health benefits of unsaturated fats. For 
example, whole fruit and total fruit are now separate items, in order to operationalize the 
recommendation to consume more whole fruit than fruit juices; and the maximum 
standard for fatty acids is based on the ratio of monounstaturated fatty acids (MUFA) 
plus polyunstaturated fatty acids (PUFA) to saturated fatty acids (SFA).
138
  
The energy density approach adopted in the construction of the HEI-2010 adjusts 
for energy intake. In contrast to the food-based adequacy components of the HEI-2010 
where assigning the minimum score of zero was easily determined by no intake for the 
specific component, arbitrary decisions had to be made for the moderation components 
(sodium, refined grains and empty calories), for assigning the minimum score because 
these components are reverse-scored and there is no scientific evidence on which to base 
the minimum scores.
138
 For example, no scientific evidence specifies how high a sodium 
intake would qualify for a score of zero. A value at approximately the 85
th
 percentile of 
the 2001-2002 population distribution of 1-day intakes was used to set the minimum 
standards for these components.
138
  
The validity of the HEI-2010 has not yet been determined for ethnic and cultural 
groups, but the index would be expected to be valid for assessing the diets of 
subpopulations for which the DGA are appropriate because the mixed dishes and sauces 
that distinguish ethnic and cultural diets would be broken down into their ingredients and 
assigned to food groups and nutrients, which are generally culturally neutral. Also, given 




predictive ability for both chronic systemic inflammation and inflammation-related 
chronic diseases will be expected to improve compared to the original HEI.  
2.2.2.c Dietary Approaches to Stop Hypertension (DASH) 
The DASH-style diet is typically high in fruits and vegetables, moderate in low-
fat dairy products, and low in animal protein but with substantial amount of plant protein 
from legumes and nuts.
139
 Evidence for the usefulness of the DASH diet plan in disease 
prevention first came from two multicenter randomized controlled feeding trials.
123,124
 
and has been incorporated in the DGA
140
 and the National Heart Lung and Blood 
Institute’s DASH eating plan.
141
 These two trials demonstrated that a diet rich in fruit, 
vegetables, and low-fat dairy products and low in saturated and total fat (DASH diet) 
reduced blood pressure and that blood pressure is further reduced when the DASH diet is 
followed in conjunction with significant reductions in sodium intake.
123,124
 The DASH 
diet therefore includes food groups and sodium, with the food groups being grains, 
vegetables, fruits, dairy, lean meat, nuts/seeds/legumes, fats/oils, and sweets. 
The DASH diet has been shown to be associated with reduced systemic 
inflammation
142





 and heart disease and stroke.
139
 Several diet indices have been 
developed to capture the DASH diet plan and evaluate associations with health outcomes. 
In a recent study, Miller et al compared four established DASH indices in regards to their 
associations with colorectal cancer in the same population (the NIH-AARP cohort).
28
  
They calculated separate indices defined by Dixon (7 food groups, saturated fat, and 
alcohol), Mellen (9 nutrients), Fung (7 food groups and sodium), and Guenther (8 food 




risk of colorectal cancer in both men and women.
28
 Miller et al concluded that “the 
consistency in findings, particularly in men for both colon and rectal cancer, suggests 
that all indices capture an underlying construct inherent in the DASH dietary pattern, 
although the specific index used can affect results.”  
There is no standardized methodology for calculating the DASH index and the 
discrepancy in the predictive ability of the four indices, where the DASH-Dixon index 
did not significantly predict colorectal cancer risk in women (in contrast to the other three 
indices) demonstrates the idea that differences in the composition of the indices and 
scoring algorithms can affect results.  
2.2.2.d Mediterranean Diet Score (Med-diet) 
A traditional Med-diet pattern typically has a high ratio of MUFA to SFA and 
omega-3 to omega-6 PUFA. It equally has a rich supply of fruits, vegetables, nuts, seeds, 
legumes, and grains. The Med diet has been widely studied with more than 20 different 
indices developed based on the Med-diet and used to evaluate health outcomes.  The 
Med-diet has been shown to be associated with reduced chronic systemic 
inflammation
4,134,146-150





 and heart disease.
140,151
 A study to compare and evaluate the 
reliability of 10 of these indices showed satisfactory performance in assessing adherence 
to the Med-diet. However, in order to improve the reliability, and concordance between 
the indices, the investigators suggested further research to standardize the number and 
selection of components and the scoring criteria of the indices.
146
 
The Med-diet score as described by Trichopoulou et al.,
152
 has been adapted and 




high intake (≥median) of each desirable component, a value of 1 to a low intake 
(<median) of each undesirable component, and a value of 0 to all other intakes. Desirable 
components may include vegetables, fruits, nuts, seeds, whole grains, legumes, fish, 
unsaturated fats, moderate alcohol, while undesirable components may include saturated 
fat, red and processed meats, and dairy products. The higher the Med diet score, the 
greater the adherence to the Med-diet pattern.
152
 
2.2.3 Empirical methods to derive dietary patterns 
Three statistical methods used to define dietary patterns include factor analysis, 
cluster analysis, and reduced rank regression.
23,125
 These so-called a posteriori 
approaches build on statistical exploratory methods driven by data.
153
 Despite the 
differences in the goal of these methods, they are similar regarding their mathematical 
foundation.
154
 There are many opportunities for subjectivity and decisions made by the 
investigators may have an impact on the number and type of patterns derived, reported, 
and analyzed. Specifically, the investigator must first decide whether or not to further 
collapse the primary dietary data into a smaller number of items for entry into the 
analysis. If the data are collapsed, a decision must be made on how to group the data. 
Next, the investigator must decide how the input variables should be treated. After the 
input variables have been entered into the procedure, a decision must be made on how 
many patterns (the output variables) need to be retained in the final solution, which 







2.2.3.a Factor analysis 
Factor analysis is a multivariate statistical technique, which uses information 
reported in nutritional assessment methods (FFQs, 24HRs, or food records) to identify 
common underlying dimensions (factors or patterns) of food consumption,
23
 by reducing 
data into patterns based upon intercorrelations between dietary items.
120
 Factor analysis 
includes both principal component analysis (PCA) and confirmatory factor analysis 
(CFA). In nutritional epidemiology, the most commonly used method to derive dietary 
pattern is PCA with varimax rotation, which enhances the difference between factor 
loadings, and allow for easier interpretability.
120
 It is an appropriate modeling approach 
for dietary patterns that are not necessarily independent of each other (that is, correlated 
patterns).
120
 Factor analysis aggregates specific food items or food groups on the basis of 
the degree to which food items in the dataset are correlated with one another. 
23
 A 
summary score for each pattern is then derived and can be used in either correlation or 
regression analysis to examine relationships between various eating patterns and 
outcomes of interest.
23
 Verasso et al., (2012) compared dietary patterns derived through 
PCA and CFA used as equivalent approaches in terms of stability and relevance and 
found that CFA may be a useful alternative to PCA in epidemiologic studies, especially 
when the sample size is small.
154
 
2.2.3.b Cluster analysis 
In contrast to factor analysis, cluster analysis aggregates individuals into 
relatively homogeneous and mutually exclusive subgroups (clusters) with similar diets 
and may use several different methods to do so (e.g., K-Means or Ward’s method).
23,120
 
Individuals can be classified into distinct clusters or groups on the basis of the frequency 




average grams of food intakes, standardized nutrient intakes, or a combination of dietary 
and biochemical measures.
23
 Compared to factors (continuous variables), clusters 
(categorical variables) may be easier to handle in the analysis since they are mutually 
exclusive and categorical. The idea that individuals have scores for all of the derived 
factors makes the concept of factor scores less intuitive than an individual belonging to a 
specific dietary pattern (or cluster).
120
 
Cluster analysis may be preferable for use in planning dietary interventions 
targeted to risk groups, as it allows the identification of subgroups and the association of 
clearly defined eating patterns with outcome measures.
119
 Although conceptually 
different, cluster analysis and factor analysis have shown similarities in grouping foods 
into patterns. For example, several studies have identified a healthy cluster, with 
important contributions from fruit, vegetables, breakfast cereals or whole grains, and low-
fat dairy products, and with some including fish and nuts.
119,120,157,158
 One limitation of 
the cluster analysis approach is lower power when comparing multiple subgroups with 
health outcomes, relative to the linear variables generated by factor analysis (PCA). This 
may be one reason why PCA has been more frequently adopted in nutritional 
epidemiology. Nonetheless, when power is adequate, cluster analysis provides clear 
descriptions of existing subgroup diets.
119
 
2.2.3.c Reduced rank regression 
Reduced rank regression (RRR) or maximum redundancy analysis determines 
linear functions of predictors (foods) by maximizing the explained variation in responses 
(disease-related nutrients). Key nutrients or biomarkers of disease (e.g., CRP, IL-6, HDL-




derived which maximize the explained variance in these responses.
159
 The classic PCA 
method selects factors that explain as much predictor variation as possible. In contrast, 
RRR extracts factors that explain as much response variation as possible.
160
 The results 
from a limited number of investigations using RRR have shown stronger relations 
between derived dietary patterns and cardiovascular disease than results from studies 
using PCA.
160,161
 However, Tucker argued that because the dietary patterns are “forced” 
to predict biological markers, the patterns are proxy variables for the biomarkers rather 
than independent variables, and that the biomarkers are known to be good predictors of 
the disease in question, therefore the dietary pattern derived is also predictive of the 
disease in the same or very similar populations.
119
 While this may be a valid argument, 
several other studies have applied RRR in different populations and settings
153,162-165
 
though with mixed results that may not be necessarily related to issues of heterogeneity in 
study populations. 
2.3 Statistical approaches for analyzing repeated measures of diet 
data  
In longitudinal observational studies of the role of diet on health outcomes, diet 
can be assessed several times during follow-up. Applying these repeated diet measures in 
the evaluation of health outcomes is not always as straightforward as using diet data at 
one point in time. Standard methods of analyzing these repeated measures require that the 
number of measurements be constant over study participants and over time, e.g., the 
proportional hazards assumption in Cox regression models,
166
 and thus most analyses 
often ignore the repeated diet measures and use only baseline data to evaluate long term 




2.3.1 Patterns of change in diet intake over time 
To create patterns of change over time in diet intake, the investigator needs to 
decide how many time points of diet data to use, though it becomes increasingly difficult 
to define patterns when using more than two time points. The data is categorized into 
quantiles and patterns are defined as movements between quantiles across different points 
in time.
167
 Quantiles must be chosen carefully to avoid too narrow or too wide definition 
of patterns. For example, tertiles provide only three categories and the investigator needs 
to decide whether change would be defined as movement of one tertile or two tertiles. A 
categorical independent variable is then created with the patterns as categories, and used 
to predict the outcome in an appropriate regression model (e.g., logistic regression model 
or Cox proportional hazards regression model). 
2.3.2 Absolute/relative changes in diet over time 
This approach would typically consider one interval of time at a time. The use of 
absolute change may be misleading because the absolute difference between two high 
diet intake values or two low diet intake values across two points in time may be 
numerically identical and when the difference is entered in a regression model, these two 
participants with different diet intake levels will be classified in the same group.  
The usefulness of percent change or relative change in classifying participants 
based on their diet intake may depend on the range of values for the specific dietary 
factor. For a composite factor that may include both positive and negative values within a 
narrow range, for example, the dietary inflammatory index, percent change may not 




anti-inflammatory direction) has a 100% change, whereas movement from 9 to 8 (another 
1 unit change in the anti-inflammatory direction) only has an 11% change, even though 
the absolute value of the change and the direction are the same.  
2.3.3 Pooled repeated observations (PRO) of diet 
This approach is a generalized person-year technique which incorporates all 
repeated diet measurements made at equally spaced intervals of time.
168
 This is the 
method used in the Framingham Study Cohort.
168,169
 The method as originally proposed 
by Wu and Ware treats each time interval as a mini-follow-up study and pools 
observations across all intervals to examine the short-term development of disease.
166
 The 
outcome for this method is assumed to occur once (that is, event/no event), in contrast to 
other sampling designs in which the outcome is also measured repeatedly over time.
166
  
In analyses using only baseline diet data, repeated observations are ignored. These 
observations are time dependent and since individuals change over time, this data which 
could influence the outcome is lost. The PRO method uses all of this data and updates the 
risk factors or diet data and persons at risk at the beginning of each observation 
interval.
168
 For example, if 500 persons were enrolled in a study and at the end of the first 
interval, 30 were diagnosed with the disease of interest, while 20 were lost to follow-up 
or died of other causes, these 50 persons are removed from the population at risk and the 
remaining 450 become at risk for the next interval and so on till the last interval. The data 
obtained from all intervals is then pooled to yield a sample from which interval 
predictions for disease can be examined as opposed to one long term prediction as would 






Three main assumptions underlie the PRO method, which include the following: 
1) the time at which data is recorded is not relevant to the occurrence of an event; for 
example, the probability of developing disease among persons with the same risk profile 
in the first interval is the same as in the ninth interval, 2) the relation between risk factors 
(e.g., diet) and outcome is independent of time, that is, there are no secular trends, and 3) 
the current risk profile is all that is needed to predict risk in the next interval, meaning 
that a person’s  past history is not important in this prediction.
168
 
Wu and Ware proposed a general logistic regression model to incorporate 
repeated measurements in predicting a dichotomous outcome.
166
 When the three 
assumptions listed above are applied to this model, it reduces to the PRO method.
168
 The 
PRO method can also be implemented using the complementary log transformation [(-log 
(1-p)] for the conditional probability of survival in an interval, proposed by Prentice and 
Gloeckler.
170
 These two regression models produce similar results when the intervals are 
short and the outcome is rare compared to number of persons at risk for the outcome.
171
 
2.3.4 Cumulative average diet  
The incidence of the outcome in an interval going forward can be related to the 
cumulative average of diet intake calculated from the preceding intervals. For example, 
the incidence of the outcome from year 3 going forward can be related to the cumulative 
average of diet data from baseline, years 1 to 3, while the incidence of the outcome from 
year 5 going forward can be related to the cumulative average of baseline, years 1-5 diet 
data. The averages can be calculated unweighted or weighted. For example, if previous 
diet history is hypothesized to influence the outcome more than current diet, more weight 




colleagues related incidence of cardiovascular disease in two-year intervals, to 
cumulative average fat intake from all preceding intervals, in a study comparing 
approaches for modeling repeated dietary measurements.
172
 To avoid the possibility of 
change of diet due to subclinical disease, outcomes that developed during the period for 
which diet is being averaged can be excluded from analyses. Exclusion of previously 
diagnosed cases also ensures that only participants at risk of developing the outcome 
going forward are included in the models 
2.4 Risk factors for colorectal cancer 
Colorectal cancer (colon and rectum cancers combined) is the third (after lung and 
breast cancer) most commonly diagnosed cancer and the second leading cause of cancer-
related deaths in the US.
173
 The American Institute for Cancer Research (AICR) 
estimates that half of colorectal cancers can be prevented by healthy lifestyle habits. In 
total, close to 400,000 cases of colorectal cancer in the United States can be prevented 
each year by eating a healthy diet, undertaking regular physical activity, maintaining a 
healthy weight and limiting alcohol consumption.
174
 This suggests that colorectal cancer 
is one of the most preventable types of cancer. An analysis of colon cancer risk factors in 
women found reduced risk for current postmenopausal hormone use, being physically 
active, taking aspirin, and being screened. Women who smoked, had a consistently high 
relative weight, had a low physical activity level, consumed red or processed meat daily, 
were never screened, and consumed low daily amounts of folate, had almost a 4-fold 
higher cumulative risk of colon cancer by age 70 years. The study also found that for 
women with a high risk factor profile, adopting a healthier lifestyle could dramatically 






2.4.1 Dietary patterns 
The 2011 Continuous Update Project report of the WCRF/AICR, on colorectal 
cancer found that consuming foods containing fiber and being physically active reduces 
colorectal cancer risk, while having excess body fat, alcohol, and intake of red and 
processed meats increase risk.
174
 The WCRF/AICR “Second Expert Report” indicated 
that there is convincing evidence linking specific dietary factors to colorectal cancer risk, 
but suggested the examination of broad patterns of diet as a way of understanding the 
causal relationship between diet and cancer development.
11
 The field of dietary patterns 
research has been growing rapidly, with five systematic reviews/meta-analyses 
examining the association between dietary patterns and colorectal cancer risk, published 
between 2010 and 2013.
176-180
 However, none of the studies included in these reviews 
examined associations between changes in dietary patterns and colorectal cancer risk. 
Despite some differences in design, methods and population characteristics of the 
individual studies included in the different reviews, all five reviews produced remarkably 
consistent results on the associations between the dietary patterns identified and risk of 
colorectal cancer. Results from a posteriori patterns generally showed a reduced risk of 
colorectal cancer from consuming a plant-based pattern characterized by a high intake of 
fruits and vegetables, legumes, and some dairy, while an animal-based pattern 
characterized by high intake of red/processed meat, refined gains, and added sugars was 
associated with increased risk.
28,30,41,42,176,177,180-182
 
 The consistency of results despite differences in the number, type and quantity of 
foods in the identified patterns between different populations could mean that specific 




based dietary pattern to have a beneficial or detrimental effect respectively, on colorectal 
cancer risk.
180
 The reviews also included results from a priori diet quality indices such as 
DASH, HEI, aHEI and Med Diet. Higher scores on the dietary indices showed a 
protective association with colorectal cancer risk. These indices share similar features 
such as the emphasis on whole grains, fruits and vegetables intakes and the penalization 
of excessive intake of animal products.
177,180
 These features broadly align a priori dietary 
patterns with the patterns that have been identified using a posteriori methods. 
However, these findings are heterogeneous by gender and anatomic subsite of 
colorectal cancer. There has been more consistency in findings for colon cancer than for 
rectal cancer. In the review by Megalhaes et al., there were significant and similar 
findings for proximal and distal colon tumors but no significant association with rectal 
cancer.
179
 Miller et al., found more consistent results for a priori patterns and colorectal 
cancer in men,
177,183
 while findings from a posteriori patterns were less clear, with four of 




Current data do not place emphasis on the analysis of changes over time in dietary 
patterns in relation to colorectal cancer risk, despite the idea that dietary behavior is not 
stable over time and dietary changes may impact colorectal cancer risk estimates 
differently than diet assessed at only one point in time. Findings of the association 
between dietary patterns and colorectal cancer risk have been consistent despite 
differences in the composition of a posteriori and a priori dietary patterns. The majority 
of studies have been conducted in North America or European populations including 




populations will be needed to determine the impact of sociodemographic factors 
(including gender) on the association between dietary patterns and risk of colorectal 
cancer. 
2.4.2 Smoking and alcohol intake 
Carcinogens from tobacco reach the colorectal mucosa through either the gut or 
the circulatory system and could damage or alter the expression of important cancer-
related genes.
184
 Tobacco smoking has consistently been associated with colorectal 
adenomas (precursors of colorectal cancer)
185
 but not with colorectal cancer until 
recently. It has been suggested that the reason for this discrepancy may be a 35- to 40-
year lag time between exposure and disease, which would not be captured by earlier 
studies and studies with shorter follow-up.
186
 Recent investigations, with more thorough 
measurement of smoking exposure and longer exposure periods, have reported a positive 
association between cigarette smoking and the risk of colorectal cancer.
184,187,188
 Paskett 
et al., investigated the associations between cigarette smoking and colorectal cancer in 
the Women’s Health Initiative, and found that active exposure to cigarette smoking 
appears to be a risk factor for rectal cancer but not colon cancer.
189
 Several systematic 
reviews and meta-analyses have been conducted with the consistent conclusion that 
cigarette smoking significantly increases colorectal cancer risk.
184,190
 There are however, 
inconsistencies relative to colorectal cancer subsite, with some studies showing positive 
results only for the rectum.
189,191
  
With the considerable evidence linking smoking to higher risk of colorectal 
cancer, it is also important to consider the impact of quitting smoking on risk attenuation. 




smoking history and colorectal cancer risk, researchers found that colorectal cancer risk 
remained increased for about 25 years after quitting smoking, and the pattern of decline 
in risk varied by colorectal cancer subsite.
192
 A study that examined lifetime smoking 
history and incidence of colorectal cancer in a large cohort of men followed for more 




The International Agency for Research on Cancer (IARC) concluded that the 
burden of alcohol-associated cancer (including colorectal cancer) is substantial and  
needs to be considered when making public health recommendations on alcohol 
consumption,
194
 though unresolved  issues relative to anatomical site (colon/rectum) 
remain. A meta-analysis of 27 cohort and 34 case-control studies found strong evidence 
(with dose-response) for an association between alcohol drinking of >1 drink/day and 
colorectal cancer risk.
195
 Several other meta-analyses have supported a positive 
association between alcohol intake and colorectal cancer risk.
196-199
 Acetaldehyde may be 
predominantly responsible for alcohol-associated carcinogenesis. Acetaldehyde is 
carcinogenic and mutagenic, binds to DNA and proteins, destroys folate and results in 
secondary hyperproliferation.
200
 Acetaldehyde is produced by tissue alcohol 
hydrogenases, cytochrome P 4502E1 and through bacterial oxidative metabolism in the 
upper and lower gastrointestinal tract.
200
 
2.4.3 Overweight/obesity and physical activity 
In 2001, the IARC convened a panel of international experts to discuss the role of 
overweight, obesity and lack of physical activity in cancer prevention and control. The 




the risk of cancers of the colon, breast (in postmenopausal women), endometrium, 
kidney, and adenocarcinoma of the esophagus.
201
 Regarding physical activity, the IARC 
panel judged also that there was sufficient evidence from human studies for a cancer-
preventive effect of physical activity against cancers of the colon and breast.
201
 The 
WCRF/AICR 2010 CUP panel on colorectal cancer reviewed the most recent evidence on 
physical activity and colorectal cancer and concluded that there was convincing evidence 
that higher levels of physical activity, within the range studied, protect against colon 
cancer, with evidence of dose-response. The report further indicated that the effect is 
stronger for colon cancer; but with no evidence of an effect for rectal cancer. The effect 
was strong and consistent in men, but less so in women and there was plausible evidence 
for mechanisms of action in humans.
174
 Evidence from the European Prospective 
Investigation into Cancer and Nutrition (EPIC) on the association between adherence to 
the WCRF/AICR recommendations on weight management and physical activity, showed 
that risk reduction in participants in the fourth and fifth categories of the adherence score 




One major class of mechanisms that may form a physiological and causal link 
between excess body weight, physical inactivity and cancer risk are alterations in the 
metabolism of endogenous hormones, including insulin, bioavailable sex steroids, 
insulin-like growth factor (IGF-I), IGF-binding proteins (IGFBPs)
174,201,203
 and chronic 
low-grade inflammation.
204
 Obesity increases insulin resistance and associated changes in 
blood values (high glucose, free fatty acids, insulin, and IGF-1). These circulating factors 






 Sustained moderate physical activity raises the metabolic rate and increases 
maximal oxygen uptake. In the long term, regular periods of such activity increase the 
body’s metabolic efficiency and capacity, and so have a beneficial effect on body fatness. 




2.4.4 Regular use of Non-steroidal anti-inflammatory drug (NSAID) 
Several studies have suggested a protective effect of aspirin and non-aspirin 
NSAIDs on colorectal cancer
79,83,84
 but some studies have failed to show a beneficial 
effect. The effect of aspirin on the risk of cancer among healthy women has been 
examined in the Women Health Study, a randomized controlled trial with an average 
follow-up time of 10.1 years. A dose of 100mg of aspirin was administered in the 
intervention group every other day against a placebo in the control group. The outcome 
was confirmed cancer of any site. This trial concluded without enough evidence that 
alternate day use of low-dose aspirin for an average 10 years of treatment lowers the risk 
of total cancer, breast, colorectal, or other site-specific cancers.
206
 Another randomized 
controlled trial examined the association between regular use of low-dose aspirin and 
incidence of invasive and noninvasive colorectal tumors. The aspirin arm was terminated 
after a mean follow-up of 5 years. The relative risk of developing colorectal cancer for 
aspirin compared with placebo was 1.15 (95%CI 0.80–1.65), with no significant trend for 
decreasing risk by year of follow-up.
207
  
In contrast, two large meta-analyses have demonstrated a beneficial effect of 
aspirin and non-aspirin NSAIDs on colorectal cancer development. In 2007, the US 






one examined the benefits and harms of non-aspirin NSAIDs and cyclooxygenase (COX-
2) inhibitors for the prevention of colorectal cancer and adenoma. Colorectal cancer 
incidence was lower with non-aspirin NSAIDs in cohort studies (RR; 0.61, 95%CI; 0.48, 
0.77) and case-control studies (RR; 0.70, 95%CI; 0.63, 0.78).
84
 Risk of colorectal 
adenoma was also reduced with non-aspirin NSAIDs use in cohort studies (RR; 0.64, 
95%CI, 0.48, 0.85) and case-control studies (RR; 0.54, 95%CI, 0.40, 0.74]) and by COX-
2 inhibitors in randomized, controlled trials (RR; 0.72, 95%CI, 0.68 to 0.77).
84
 The other 
meta-analysis examined the benefits and harms of employing aspirin for the 
chemoprevention of colorectal cancer. In this study, regular use of aspirin reduced the 
incidence of colonic adenomas in randomized clinical trials (RR; 0.82, 95%CI, 0.70 to 
0.95), case-control studies (RR; 0.87, 95%CI, 0.77 to 0.98), and cohort studies (RR; 0.72, 
95%CI, 0.61 to 0.85).
83
 In cohort studies, regular use of aspirin was associated with 
reduced risk of 22% for colorectal cancer.
83
 
Despite this evidence showing that aspirin and non-aspirin NSAIDs appear to be 
effective at reducing the incidence of colonic adenoma and colorectal cancer, especially 
if used in high doses for a prolonged period of time, the USPSTF currently recommends 
against the use of aspirin and non-aspirin NSAIDs for the prevention of colorectal cancer 
in individuals at average risk for the disease (D recommendation). This is likely due to 
adverse side effects such as cardiovascular events and gastrointestinal harms.
84
 This 
recommendation may likely change as more evidence accumulates.  
2.5 Risk factors for breast cancer 
Breast cancer is the most commonly diagnosed cancer in women, and  is the 






Breast cancer in women accounts for about a third of all cancer cases and about 15% of 
all cancer deaths among women in the United States. Risk factors include diet, physical 
activity, body size, reproductive and hormonal factors, among many other factors. The 
role of diet in breast cancer risk is of great interest as a potentially modifiable risk factor. 
2.5.1 Dietary patterns 
Most of the established risk factors for breast cancer such as family history, 
lactation, and reproductive history are generally not modifiable. Epidemiological studies 
have shown that the risk of breast cancer varies with diet - a potentially modifiable factor 
– though the evidence is inconsistent.
41-47,181,182,208-211
 Dietary patterns contain a complex 
mix of foods, nutrients and other compounds that could influence breast cancer risk in 
ways not detected by studies of individual foods and nutrients. Evidence shows a positive 
association between the Western-style dietary pattern (rich in added sugar, refined grains, 
red and processed meats, and fried foods) and increased risk.
41,43,212-214
 Studies have also 
observed a decreased risk with the prudent-type dietary pattern (rich in fruits, vegetables, 
whole-grains, legumes, nuts, olive oil and fish),
43,181,182,212-217
 but other studies have not 
found significant associations with any of these dietary patterns identified by a posteriori 
methods except in subgroup analyses in some studies.
46,180,181,212,218,219
 In the Black 
Women’s Health Study, the prudent pattern was weakly associated with lower risk 
overall, but was significantly associated with lower risk in normal weight women and in 
women with estrogen receptor negative breast cancer.
220
 A meta-analysis of 15 
prospective studies found that high intake of fruits, and fruits and vegetables combined, is 
associated with a weak reduction in risk of breast cancer with no dose-response.
221
 




significant associations were observed with increasing consumption of fruit and 
vegetables.
219
 Other dietary patterns investigated are the vegetarian diet. One study found 
no significant association between a vegetarian versus non-vegetarian diet and breast 
cancer risk,
222
 while there was a non-significant inverse association between 




Regarding a priori dietary patterns, an index derived from 23 recommended food 
items was not associated with breast cancer risk in one study.
224
 Similarly, in the Nurse’s 
Health Study, an investigation of the association of several dietary indices and 
postmenopausal breast cancer found no significant association with any of the indices, 
except when stratifying by hormone receptor status of the cancer. Women who scored 




Studies of the association between dietary patterns and breast cancer risk have 
been conducted in populations other than North Americans and Europeans. Some reports 
indicate that dietary patterns rich in vegetables and seafood are associated with a 
decreased breast cancer risk in Korean women,
226,227
 and Chinese women.
228
 Findings 
from one study suggest that a diet characterized by low intake of meat/starches and high 
intake of legumes is associated with a reduced risk of breast cancer in Asian Americans, 
213
 while another study found evidence of an inverse association between a healthy 
dietary pattern and breast cancer risk among Iranian women.
212
  A Japanese study found 
that the prudent dietary pattern is negatively associated with breast cancer risk, while the 






 It is also important to note that none of the published studies examined the 
association of changes in dietary patterns and risk of breast cancer, though changes in 
dietary patterns may impact risk differently than dietary patterns assessed at only one 
point in time. 
2.5.2 Overweight/obesity and physical activity 
Obesity is a state of chronic systemic low-grade inflammation.
229
 Adipose tissue 
is now known to secrete a growing number of inflammatory mediators (adipokines) 
including CRP. The secretion of these inflammatory mediators is increased in obesity,
230
   
and they regulate physiological and pathological processes, including immunity and 
inflammation.
229
 There is increasing epidemiologic evidence of an association between 
BMI and energy expenditure and the risk of breast cancer. Women who are overweight or 
obese, especially women who gain weight throughout adulthood, are at an increased risk 
for developing breast cancer after menopause.
231-233
 Conversely, overweight women are 
at reduced risk for developing breast cancer in the premenopausal years.
234
 A pooled 
analysis of cohort studies showed that BMI has significant inverse and positive 
associations with breast cancer among pre- and postmenopausal women, respectively. 
Compared with premenopausal women with a BMI of less than 21 kg/m
2
, women with a 
BMI exceeding 31 kg/m
2
 had a relative risk of 0.54 (95%CI; 0.34, 0.85). In 
postmenopausal women, the relative risk for these women was 1.26 (95%CI; 1.09, 
1.46).
235
 A meta-analysis to assess the strength of associations between BMI and different 
sites of cancer estimated that each 5 kg/m
2
 increase in BMI was associated with a 12% 
increased risk of postmenopausal breast cancer (RR; 1.12; 95%CI, 1.08, 1.16).
236
 In 




replacement therapy; users are at higher risk compared to non-users, and by estrogen 
receptor/progesterone receptor (ER/PR) status; with women having ER+/PR+ tumors 
being at higher risk compared to ER-/PR- tumors.
231,233,237
 A meta-analysis of 9 cohorts 
and 22 case-control studies, further confirmed that the association between BMI and 
breast cancer risk is dependent on menopausal status and ER/PR status.
237
 
Studies have shown that physical activity increases concentrations of a number of 
cytokines with anti-inflammatory effects such as IL-1ra (interleukin-1 receptor 
antagonist) and IL-10 and inhibits the production of the pro-inflammatory cytokine 
TNFα.
238
 Physical activity also has been shown to be associated with reduce 
concentrations of some pro-inflammatory cytokines such as CRP and other biomarkers of 
inflammation.
239-242
 These results consistently show that physical activity reduces chronic 
inflammation – a crucial process in cancer development. 
Physical activity has been shown to reduce breast cancer risk. A study 
investigating the relation between recreational physical activity (RPA) and breast cancer 
risk, found that RPA at any intensity level during the reproductive and postmenopausal 
years was associated with reduced breast cancer risk and that substantial postmenopausal 
weight gain may eliminate the benefits of RPA.
243
 Physical activity also was found to be 
associated with reduced breast cancer risk in the WHI, with longer duration providing the 
most benefit.
244
 The association between physical activity and postmenopausal breast 
cancer risk has been confirmed consistently enough that the US Department of Health 
and Human Services Physical Activity Guidelines Advisory Committee concluded in 
2008 that “strong evidence demonstrates that, compared with less active persons, more 






2.5.3 Hormone replacement therapy and oral contraceptive use 
Evidence shows that oral contraceptive use increases a young woman's risk of 
breast cancer. A multisite case-control study analyzed data on women younger than 45 
years of age (to maximize opportunities for extended exposure) who used oral 
contraceptives throughout their entire reproductive years. In this population of younger 
women, use of oral contraceptives for 6 months or longer was associated with an 
increased risk for breast cancer of 30% (OR,1.3; 95%CI, 1.1, 1.5).
246
 There was also a 
significant dose-response relationship. To investigate the possibility that chance or bias, 
including selective screening of contraceptive users, contributed to the putative 
association, an evaluation of screening histories and methods of diagnosis failed to 
support the speculation that associations could be due to selective screening.
246
 Among 




Increased risk of breast cancer with combined use of estrogen and progesterone 
has been reported in some studies.
247,248
 In the study by Schaier et al., the risk was greater 
for lean women, but there was no evidence of increased risk in heavier women,
248
 which 
is similar to the finding in the collaborative reanalysis.
249
 This effect modification by 
BMI is contrary to the study results that endogenous estrogen increases risk of breast 
cancer, given that overweight and obese women have relatively higher endogenous 
estrogen levels than lean women due to non-ovarian synthesis of estrone as a result of the 
peripheral conversion of androgens.
248
 Another study reported that obese postmenopausal 
women had a greater increase in circulating free estradiol in response to oral estrogen 






The association between exogenous estrogen use and breast cancer risk lacked 
clinical trial support until 1993 when the WHI began two randomized placebo-controlled 
trials that separately evaluated estrogen plus progestin (in women with an intact uterus) 
as well as estrogen alone (in women with a previous hysterectomy)
251
 (NB: In the 
absence of a uterus, estrogen treatment is the only way to relieve a women of hot flashes 
or other menopausal symptoms, and in the estrogen-alone trial, there would be 
confounding by endogenous estrogen if the uterus is present). After a mean follow-up of 
5.3 years there was a slightly increased risk of breast cancer, HR, 1.26; 95%CI, 1.00, 
1.59.
251
 However, women reporting prior use of estrogen plus progesterone experienced 
higher risk for breast cancer associated with estrogen plus progesterone use than those 
who never used postmenopausal hormones. Longer duration of prior use of estrogen plus 
progesterone appeared to have a cumulative effect of estrogen plus progestin on risk of 
incident breast cancer and these effects were not found to be modified by age, 
race/ethnicity, family history, parity, age at first birth or BMI.
251
 
In contrast to the substantial evidence linking exogenous hormone use (combined 
estrogen plus progestin) with increased breast cancer risk, the parallel WHI estrogen-
alone trial showed an unanticipated potential reduction in breast cancer risk (HR, 0.77; 
95%CI, 0.59, 1.01) in the estrogen-alone group compared to the placebo group after 7.1 
years of follow-up.
252
 Differences in breast cancer screening between the intervention and 
placebo groups did not explain the observed effects.
40
 The suggestion of a reduced risk 
for breast cancer motivated Stefanick et al to conduct a detailed analysis of the WHI 
estrogen-alone trial data focusing only on breast cancer outcome. Their main analysis 




cancer (HR, 0.80; 95%CI, 0.62, 1.04).
253
 However, in adherence-adjusted analyses that 
censored follow-up 6 months after a woman became nonadherent, a larger and significant 
reduction in the incidence of invasive breast cancer was observed in the estrogen-alone 
group compared with the placebo group (HR, 0.67; 95%CI, 0.47-0.97) and the risk did 
not differ by estrogen or progesterone receptor status of the cancer.
253
 
No significant interaction of exposure to exogenous hormone and BMI on breast 
cancer risk was observed in either the estrogen-alone trial or in the combined estrogen 
plus progestin trial.
251-253
 The differences in the results of the two WHI trials strongly 
suggest a role for progestin in increasing breast cancer risk. The biological mechanisms 
underlying an effect of exogenous hormones on the breast are complex. One hypothesis is 
that progesterone does not down-regulate estrogen and progesterone receptors in the 
breast may contribute to its adverse effects.
254
 It is paradoxical however, that the addition 
of exogenous estrogen by use of conjugated equine estrogen in the WHI trial
253
 and the 
reduction of endogenous estrogen by use of aromatase inhibitors (exemestane) in the 
MAP.3 trial
255
 both reduced risk of breast cancer incidence. The conceptual model that 
breast cancer growth may be stimulated or inhibited solely by the respective addition or 
withdrawal of estrogen thus falls apart.  
In summary, the long-term effect of estrogen use on the risk of breast cancer is 
still an open question. Women exposed to exogenous hormones (especially combined 
estrogen and progestin) are at increased risk for breast cancer. The risk increases with 
duration of use, but also reduces after cessation of use of exogenous hormones and has 
largely, if not wholly disappeared after 2 to 5 years post-cessation. The increase in risk 




between risks and benefits should be carefully assessed. In this assessment, it is important 
to consider the type of hormone as well as individual characteristics of the woman, such 
as BMI. 
2.5.4 Demographic factors 
Many demographic factors influence the incidence and survival rates from breast 
cancer. The disease is more common in older women, among women in upper rather than 
lower social classes, among women who never have been married, among women living 
in urban areas, and among European Americans than African Americans, at least among 
those over age 50.
256
 
The strongest risk factor for breast cancer is age. A woman’s risk of developing 
the disease increases as she gets older. That is because with more years of life, there are 
more opportunities for genetic damage (mutations) in the body, and as we age, our bodies 
are less capable of repairing genetic damage. According to Surveillance, Epidemiology, 
and End Results (SEER) program statistics from 2005-2009, the median age at diagnosis 
for cancer of the breast was 61 years of age. Approximately 0% were diagnosed under 
age 20; 2% between 20 and 34; 10% between 35 and 44; 22% between 45 and 54; 25% 




European American women are slightly more likely to develop breast cancer 
(age-adjusted incidence rate: 127.3 per 100,000 women) than African American (121.2 
per 100,000 women), Hispanic, and Asian women. But African American women are 




diagnosed at younger ages. African American women are also more likely to die from 
breast cancer. Based on the SEER data for patients who died in 2005-2009 in the US, the 
breast cancer mortality rate for African American women is 31.6 per 100,000 women 
compared with 22.4 per 100,000 women for European American women.
257
 Some of 
these differences in outcomes may be due to tumor biology (e.g., higher prevalence of 
triple negative tumors in African Americans).
258
 Compared to European American 
women, women of African ancestry tend to have more aggressive breast cancers that 
present more frequently as estrogen receptor-negative (ER-) tumors.
258-260
 Triple negative 
comprise approximately 15% of breast cancers and have been associated with high-grade 
histology, aggressive clinical behavior, and poor survival.
261
 Other possible explanations 
for racial disparities in aggressiveness of disease include less access to mammography 
screening and lower quality medical care,
262,263
 as well as various lifestyle patterns 
(eating habits and weight issues for example) that are more common in some ethnic 
groups than in others. In a study to evaluate differences in the stage and biology of breast 
cancer between African American and European American women who had a screening 
mammogram, Grabler et al., found that African American women in the regularly 
screened population were less likely than irregularly screened African American women 
to have ER- breast cancers (26% vs. 36%, p<0.05), PR- breast cancers (35% vs. 46%, 
p<0.05), and poorly differentiated breast cancers (39% vs.53%, p<0.05).
264
 European 
American women in the irregularly screened population also had worse prognostic 
factors than European American women in the regularly screened population, though 
these were not statistically significant.
264
 Regular screening for breast cancer may thus 





3.1 Statement of research aims and hypotheses 
The overall aim of this study was to characterize longitudinal trends in the 
inflammatory potential of the diet and then evaluate the association of longitudinal 
changes in the inflammatory potential of diet and risk of colorectal cancer and breast 
cancer in the WHI. Our overall hypothesis is that long term changes in dietary behavior 
towards increased consumption of pro-inflammatory diets increases the risk of cancer 
over time. 
In specific aim #1, we investigated the stability of the inflammatory potential of 
diet over time using the dietary inflammatory index (DII). In this aim we hypothesized 
that the inflammatory potential of diet significantly changes over time and is influenced 
by social, demographic and clinical factors. In specific aim #2, we examined the 
association between the inflammatory potential of diet and risk of colorectal cancer with 
the hypothesis that a sustained high level of dietary inflammatory potential over time, 
increases risk of colorectal cancer. In specific aim #3, we examined the association 
between the inflammatory potential of diet and breast cancer in postmenopausal women, 
 
50 
with the hypothesis that a sustained high level of dietary inflammatory potential over 
time, increases risk of breast cancer in postmenopausal women. Specific research 
questions have been restated in section 3.6, before the description of the statistical 
methods for each of the three aims. 
3.2 Description of the study population 
The WHI study is a large and complex clinical investigation of strategies for the 
prevention and control of some of the most common causes of morbidity and mortality 
among postmenopausal women. The design of the WHI has been described in detail 
elsewhere.
40
 Briefly, The WHI began in 1992, spanning across 40 sites in the United 
States, and enrolled a total of 161,808 women between 1993 and 1998 and included
 
full-
scale randomized controlled trials, with an average of 11.3 years of follow-up until 
September 30, 2010. The WHI enrolled 93,676 women into the OS and 68,132 
participants into clinical trials (CT).
265
 The WHI CT included: the DMT component, 
n=48,835, the Hormone Therapy component (HT, estrogen-alone or estrogen plus 
progestin, n=27,347). Participants enrolled in at least one of the clinical trial components 
were screened for eligibility and invited to join the calcium and vitamin D component 
(CaD, n=36,282) at their first or second annual clinic visits. For the DMT, women were 
randomly assigned to a usual-diet comparison group (n = 29,294) or an intervention 
group with a 20% low-fat dietary pattern with increased vegetables, fruits, and grains (n = 
19,541). At baseline, the mean age was 63 years and about 18% of the women were from 
ethnic minority groups including: 9.1% African-Americans (n=14,618), 4% Hispanics 
(n=6,484), and 2.6% Asians (n=4,190). Women who proved to be ineligible for, or who 
 
51 
were unwilling to enroll in the CT components were invited to be part of the prospective 
cohort of women in the OS.
40
  
Exclusion criteria for both the OS and CT included any medical condition 
associated with a predicted survival of less than three years, alcoholism, other drug 
dependency, mental illness (e.g., major depressive disorder), dementia, active 
participation in another intervention trial and not likely to live in the area for at least 3 
years. Demographic information and dietary data were obtained by self-report using 
standardized questionnaires. Certified staff performed physical measurements, including 
blood pressure, height and weight, and blood samples at the baseline clinic visit. Women 
were further excluded from the DM if their diets were assessed to have <32% energy 
from fat.
266
 The WHI protocol was approved by the institutional review boards at the 
Clinical Coordinating Center at the Fred Hutchinson Cancer Research Center (Seattle, 
WA) and at each of the 40 Clinical Centers.
14
  
3.3 Diet assessment 
During baseline screening for the WHI, all participants completed a standardized 
food frequency questionnaire (FFQ) developed for the WHI to estimate average daily 
nutrient intake over the previous three-month period. At follow-up, the FFQ was 
completed at year 3 for all the observational study participants and for all participants in 
the DMT at year 1, and a random third of DMT participants from year 2 onwards. The 
three sections of the WHI FFQ included 19 adjustment questions related to type of fat 
intake, 122 composite and single food line items asking about frequency of consumption 
and portion size, and four summary questions that asked about the usual intake of fruits 
and vegetables and added fats for comparison to information gathered from the line 
 
52 
items. The nutrient database, linked to the University of Minnesota Nutrient Data System 
for research (NDSR), is based on the US Department of Agriculture Standard Reference 
Releases and manufacturer information. This FFQ has demonstrated good comparability 
to 24-hour dietary recall interviews and food records in the WHI.
266
 For all three study 
aims, we used all the FFQs in the OS and DMT and calculated the DII at eleven different 
time points.  
3.4 Outcomes assessment 
For aim #1, changes in the DII over time, calculated at 11 time points constituted 
our outcome of interest. A detailed description of the DII is provided in section 3.5. In 
aims #2 and #3, where colorectal cancer and breast cancer were the outcomes of interest, 
the DII was the main exposure of interest.  
The WHI outcomes ascertainment and adjudication methods have been previously 
described.
267
 Briefly, physicians in the Clinical Centers, the Clinical Coordinating Center, 
and the National Institutes of Health (NIH) classified WHI outcomes. In the first stage, 
the local Clinical Center physician adjudicator reviewed the documents and assigned a 
diagnosis. All locally adjudicated primary and safety endpoint events of each trial 
component were then centrally reviewed. A fraction of locally adjudicated secondary 
endpoints were also referred for central adjudication for quality control purposes. The 
primary results for each clinical trial component were based on data derived from central 
adjudication. To minimize potential bias in the ascertainment and classification of 
outcomes, WHI required that local and central physician adjudicators not be exposed to 
any information that could result in potential unblinding, including participant contact or 
other aspects of the research record. 
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Invasive breast and colorectal cancers were documented and coded according to 
primary site, anatomic subsite, diagnosis date, extent of disease (stage, tumor size, and 
laterality), tumor morphology (behavior, grade, histology) her2neu status and estrogen 
and progesterone receptors status (breast cancer only). We have chosen to focus on breast 
and colorectal cancers in this dissertation because these cancers have been associated 
with diet and inflammation in previous studies and because these were primary or 
secondary endpoints in WHI allowing for adequate numbers of cases for analyses. 
Incident invasive and in situ (ductal and lobular carcinoma in situ) breast cancers, 
including second primaries, were ascertained and adjudicated. Incident invasive and in 
situ colon and rectal cancers were determined. Recurrent cancers were not included. All 
cancer related hospitalizations, surgeries, procedures, diagnostics or treatments for each 
first self-report of a malignant tumor were investigated. For the full coding of the cancer, 
pathology reports from diagnostic aspirations, biopsies, and surgeries, plus the discharge 
summary, were used.  
Since the diagnosis of some early cancers and cancer precursors is dependent on 
whether or not screening has occurred, there was potential for over-reporting of 
diagnoses in some arms of the study, particularly the unblinded intervention arm of the 
DMT component. For this reason and for safety purposes in the HT component, all 
clinical trial participants had regular screening mammograms as part of study protocol. 
Screening for colorectal cancer was not done in WHI. At each follow-up contact (semi-
annually in the clinical trial, and annually in the observational study), however, 
information on screening procedures for colorectal cancer was collected, including: fecal 
occult blood testing, flexible sigmoidoscopy, and colonoscopy.  
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 of the DII  has been described elsewhere. The 
goal in developing the DII was to create a score for specific foods and dietary 
constituents thought to positively or negatively affect levels of inflammation.  All 
research articles through the year 2010 that were identified as assessing the role of one or 
more of 45 different foods and dietary constituents on specific inflammatory markers 
were used to create the scores. Due to the large number of articles on inflammation, the 
literature search was limited to six well-established inflammatory markers: CRP, IL-1β, 
IL-4, IL-6, IL-10, and TNFα out of which CRP, IL-1β, IL-6 and TNF-α are considered 
pro-inflammatory biomarkers and IL-4 and IL-10 are considered anti-inflammatory 
cytokines. A total of 1,943 research articles were reviewed and scored in the creation of 
the DII. 
One of three possible values was assigned to each article based on the effect of 
the food parameter on inflammation: “+1” was assigned if the effects were pro-
inflammatory (significantly increased IL-1B, IL-6, TNFα, or CRP or decreased IL-4 or 
IL-10); “-1” if the effects were anti-inflammatory (significantly decreased IL-1B, IL-6, 
TNFα, or CRP or increased IL-4 or IL-10) and “0” if the food parameter was not 
significantly associated with the inflammatory marker.  Full details of the scoring 
algorithm are described in this reference.
38
 
Articles were first weighted by study design, with clinical trials in humans 
receiving the greatest weight (i.e., 10 of possible 10) to cell culture experimental studies 
receiving the lowest weight (i.e., 3 of possible 10). Using these weighted values, the pro- 
and anti-inflammatory fractions for each food parameter were calculated.  The food 
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parameter-specific overall inflammatory effect score was then calculated by: 1) dividing 
the weighted pro- and anti-inflammatory articles by total weighted number of articles and 
2) subtracting the anti-inflammatory fraction from the pro-inflammatory fraction (Figure 
3.1).  A cut point of 236, the median of the total weighted number of articles across all 
the food parameters, was chosen to indicate an optimally robust pool of literature. All 
food parameters with a weighted number of articles ≥236 were assigned the full value of 
the score. Foods and constituents with a weighted number of articles <236 were adjusted 
as follows: 1) number of weighted articles was divided by 236; 2) the fraction was then 
multiplied by the food parameter-specific raw inflammatory effect score, which resulted 
in the food parameter-specific overall inflammatory effect score.  
To avoid the arbitrariness resulting from simply using raw intake amounts 
(resulting in different units of measurement for various nutrients having large influences 
on the overall score), the DII was standardized to a representative range of dietary intake 
based on actual human consumption. This was accomplished by constructing a composite 
database representing a wide range of diets across diverse populations living in a variety 
of countries in different regions of the world. Authors of articles reporting on data from 
nutrition surveys were contacted to request access to complete datasets.  A total of 11 
such datasets were identified and used in developing the composite database.
38
   
Calculation of the DII in a given study is based on dietary intake data that are then 
linked to the global mean intake database derived from the 11 datasets.  An individual’s 
diet is then expressed relative to the standard global mean as a z-score. This is achieved 
by subtracting the standard global mean from the amount reported by the individual and 
dividing this value by its standard deviation. To minimize the effect of “right skewing,” 
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this value is converted to a percentile score.  To achieve a symmetrical distribution with 
values centered on 0 (null) and bounded between -1 (maximally anti-inflammatory) and 1 
(maximally pro-inflammatory) each percentile score is doubled and then 1 is subtracted.  
The centered-percentile value for each food parameter is then multiplied by its respective 
food parameter-specific inflammatory effect score to obtain a food parameter-specific DII 
score. Finally, all of the food parameter-specific DII scores are summed to create the 
overall DII score for an individual. More positive scores represent a more pro-
inflammatory diet, whereas more negative scores represent a more anti-inflammatory 
diet. 
3.6 Statistical analysis 
3.6.1 Statistical methods applicable to all three aims 
Confounding in all the Cox proportional hazards (PH) regression models was 
assessed using the following three questions as suggested by Szklo and Nieto:
268
 1) is the 
confounder related to both exposure (DII) and outcome (colorectal cancer or breast 
cancer)? 2) Does the exposure-outcome association seen in the age-adjusted crude model 
have the same magnitude and similar direction as the associations observed within strata 
of the potential confounder? 3) Does the exposure-outcome association seen in the crude 
model have the same magnitude and similar direction as that observed association in the 
model adjusted for the potential confounder? Confounding was not assessed in aim #1 as 
there was no specific exposure of interest in the prediction model for DII change. 
Effect modification took precedence over confounding; that is, if a variable was 
assessed to be both a confounder and effect modifier, it was treated as an effect modifier. 
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We inserted “interaction terms" of main exposure and effect modifier in the models and 
considered significant effect modification at P ≤ 0.05.  
Statistical modeling consisted of variable selection and model selection. For the 
DII prediction model in aim #1, the automated stepwise approach was used to identify 
significant predictors of DII change. In the Cox PH models in aims #2 and #3, all 
variables assessed to be confounders or significant effect modifiers were retained in the 
models. Model selection was considered in specific situations to either include or exclude 
a covariate from the model and improve the model’s overall precision. The log-likelihood 
ratio test was used for model selection. 
Participant characteristics were summarized using frequencies (percentage) for 
categorical variables and means (standard deviation) for continuous variables. All p-
values were 2-sided, and P <0.05 for aim #1 and 95% confidence intervals not including 
1 for aims #2 and #3, were considered to indicate statistical significance. All statistical 
analyses were conducted using Statistical Analysis Systems software, version 9.3 (SAS, 
Inc., Cary, NC). 
3.6.2 Statistical methods for specific aims #1  
The statistical methods for this aim were designed to answer the following four 
research questions: 1) Are there changes in dietary inflammatory potential over time? 2) 
If there are significant changes, how do demographic and lifestyle factors impact these 
changes? 3) What social, demographic and clinical factors significantly predict changes 
in DII in an observational setting? and 4) How does the change in the inflammatory 
potential of diet in an intervention setting differs from that in an observational setting? 
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We computed mean DII scores at baseline and Year 3 in the OS and at 11 
different time points between baseline and Year 10 inclusive in the DMT; and used these 
to describe changes over time in the OS, or plotted DII scores on graphs for a visual 
appraisal of the longitudinal trend, separately for the intervention and control arms of the 
DMT. Analyses were stratified by BMI, race/ethnicity and educational level. To 
determine significant differences between mean DII scores calculated at different time 
points, we constructed marginal linear regression models using generalized estimating 
equations (GEE) that adjusted for the within-subject correlation in the DII measurements, 
to calculate and compare all pair-wise contrast estimates between mean DII scores. The 
GEE model was a univariate model with time from baseline as the only independent 
variable and changes in the DII over time as the dependent variable, adjusted for multiple 
comparisons using the Bonferroni approach, and stratified in the DMT by intervention 
arm.  
Next, we utilized stepwise linear regression to construct the most parsimonious 
predictive multivariable model for change in DII from baseline to Year 3 in the OS. A 
previous WHI study investigated predictors of dietary change and maintenance in the 
DMT and included intrapersonal, interpersonal, intervention characteristics and clinical 
center characteristics as predictors.
269
 The DMT intervention moved participants toward 
an anti-inflammatory diet; therefore, predictors of dietary change investigated by Tinker 
et al are likely to predict DII change in the DMT. We therefore focused mainly on the 
potential predictors of DII change in the OS. We included the following baseline 
variables in the stepwise regression model: baseline DII, age group, BMI (kg/m
2
), 
race/ethnicity, education, smoking status,  physical activity, history of diabetes, 
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hypertension, arthritis, cancer, use and duration of estrogen-alone and of combined 
estrogen and progesterone, use of statins, anti-depressants, and non-steroidal anti-
inflammatory drugs (NSAID) (see section 4.3 for the categories of these variables). The 
entry criterion into the stepwise linear regression model was P <0.1, while the exit 
criterion was P >0.1. The stepwise model identified variables that were included in a 
multivariable linear regression model to calculate beta (β) coefficients, corresponding p-
values and the R
2 
for the overall predictive model. Participants with implausible reported 





single FFQs or missing FFQs, as well as those with missing data in the predictors in the 
final model were excluded from this analysis.  
3.6.3 Statistical methods for specific aims #2 and #3 
Statistical methods for these two aims were similar and designed to provide 
answers to the following three main questions: 1) How does long-term cumulative history 
of dietary inflammatory potential impact risk of colorectal cancer and risk of breast 
cancer? 2) How do shorter-term changes in patterns of the inflammatory potential of diet 
over time impact risk of colorectal cancer and risk of breast cancer? 3) Do risk estimates 
differ by anatomic subsite (colon, rectum) of colorectal cancer and by molecular or 
histologic subtype of breast cancer? 
We used data from 142,511 women participating in the WHI OS and DMT. 
Women with colorectal cancer or breast cancer at baseline or missing colorectal cancer or 
breast status at baseline, or those who reported breast removal at baseline were excluded, 
as well as women with implausible reported total energy intake values (≤600 kcal/day or 
≥5000 kcal/day) or extreme BMI values (<15kg/m
2





To determine how cumulative history of dietary inflammatory potential affects 
risk of colorectal cancer and breast cancer, we calculated ten cumulative averages of DII 
incrementally starting from the average between baseline and year one DII.
172
 
The cumulative average was then categorized into quintiles, and used to estimate hazards 
ratios for colorectal cancer or breast cancer in multivariable-adjusted Cox proportional 
hazards (PH) regression models, while excluding from the models colorectal cancer cases 
or breast cancer cases diagnosed prior to year one. This approach was repeated for the 
average DII of baseline, year one, and year two with cancer cases diagnosed prior to year 
two excluded to avoid the possibility of change in diet due to subclinical disease, and to 
include only participants at risk of developing cancer going forward. This approach was 
repeated until DII estimates at all time points were used.
172
 
For each time segment, Cox proportional hazards regression models were used to 
estimate hazards ratios (HR) and 95% confidence intervals (95%CI) for colorectal, colon, 
rectal cancer, and invasive breast cancer incidence, by quintiles of cumulative average 
DII, with adjustment for multiple covariates. 
To determine how changes in patterns of the inflammatory potential of diet over 
time affect risk of colorectal cancer or breast cancer, we calculated the DII from baseline 
and year 3 food frequency questionnaires (FFQ) in the OS and DMT in participants with 
at least two FFQs at these two time points. Since diet data was assessed in the OS at 
baseline and Year 3 only, we selected these two time points to maximize the number of 
participants with at least two FFQs. We categorized the DII at both time points into 
quintiles (Q) and further categorized changes in the inflammatory potential of diet based 
on quintile differences between baseline and year 3, as follows: 1) anti-inflammatory 
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stable: Q1 or Q2 at both time points or change from Q3 to Q2; 2) anti-inflammatory 
change: changes ≤ -2Q; 3) neutral inflammation stable: changes from Q2 to Q3, Q4 to Q3 
or stable at Q3 at both time points; 4) pro-inflammatory change: changes ≥ 2Q; 5) pro-
inflammatory stable: Q4  or Q5 at both time points or change from Q3 to Q4. Cox 
proportional hazards regression models were used to estimate hazard ratios (HR) and 
95% confidence intervals (95%CI) for colorectal, colon (proximal and distal), and rectal 
cancer incidence, by patterns of changes in DII, with adjustment for multiple covariates. 
Similar models were constructed for invasive breast cancer. We used AIC to determine 
the model with the best precision. Each covariate in the final model was tested for the 
proportional hazards assumption using cumulative sums of Martingale-based residuals. 
All multivariable-adjusted models included the following covariates: age, 
race/ethnicity, educational level, smoking status, diabetes, hypertension, arthritis, 
NSAIDs use, category and duration of estrogen use, category and duration of estrogen & 
progesterone use, DMT arm , BMI, and physical activity (minutes/week) as potential 
confounders. Effect modification in models for both the cumulative average DII and 
changes in the DII and cancer incidence was investigated by included 2-way cross 
product terms in the models. Potential effect modifiers included age group, BMI, 
educational level, race/ethnicity, combined use of estrogen and progesterone. We 
conducted a power analyses to determine ranges of estimated HR to be obtained in the 
analytic models given the incidence proportions (event rate) for colorectal and breast 
cancers in this study, using the PASS software program (NCSS, LLC, Kaysville, Utah) 
(Table 3.1).  
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1) 1943 articles on 45 food parameters 
identified and scored  
  
5) -World composite database for 
45 food parameters based on 
data from 11 countries 
-Calculate world mean and 
standard deviation for each of the 
45 food parameters 
4) Inflammatory effect score calculated 
from 2) and 3)  
2) Weight articles by study design and 
calculate pro- and anti-inflammation 
fractions  
3)  Adjust scores if total weighted 
articles is <236  
6) Based on available dietary intake 
data calculate z-scores and 
centered percentiles for each of the 
food parameters for each individual 
in the study, based on the world 
average and standard deviation. 
8) Sum all of the “component specific DII score 
. 
 to create the “overall DII score” for an indi 
idual. 
. 
7) Multiply centered percentile by the inflammatory effect 
score to obtain “component-sp 
 
-Calculate world mean and standard deviation for each 
of the 45 food parameters 
ci 
ic DII score.” 
Dietary intake 
made available 
to the scoring 
algorithm  
Figure 3.1: Sequence of steps in creating the DII. (adapted from Shivappa, N., 
Steck SE, Hurley TG, Hussey JR, Hebert JR, Designing and Developing a 
Literature-derived, Population-based Dietary Inflammatory Index. Public 






Estimated range of 
hazard ratios (HR) based 
on available cancer cases 
Cancer incidence 
proportion (event rate) 
Models for cumulative average DII (baseline to Year 2) 
Colorectal 1.06 – 1.19 0.0132 
Colon 1.06 – 1.21 0.0107 
Rectal 1.13 – 1.47 0.0026 
Invasive breast cancer 1.03 – 1.10 0.0455 
Models for Patterns of change in DII quintiles between baseline and Year 3 
Colorectal 1.04 – 1.12 0.0135 
Colon 1.04 – 1.14 0.0113 
Rectal 1.07 – 1.32 0.0024 
Invasive breast cancer 1.02 – 1.06 0.0518 
Triple negative BRCA 1.08 – 1.26 0.0038 
HER2+/ER- subtype 1.12 – 1.43 0.0016 
Luminal A BRCA 1.03 – 1.09 0.0270 
Luminal B BRCA 1.07 – 1.25 0.0042 
Ductal carcinoma 1.02 – 1.08 0.0338 
Lobular carcinoma 1.06 – 1.21 0.0054 
Mixed ductal/lobular 
carcinoma 
1.05 – 1.18 0.0074 
NB: power=80%, tests=2-sided, alpha=0.05, standard deviation of DII =2.30, R
2
 varied from 0.1 to 0.9 by 
0.1, and the event rate was the incidence proportion of each cancer type. (BRCA=breast cancer) 
 
Table 3.1. Estimated ranges of hazard ratios for colorectal and breast cancers based 
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Introduction: The dietary inflammatory index (DII) measured at one point in 
time has been associated with cancer risk in previous studies and repeat measures have 
been analyzed in relation to inflammatory biomarkers. However, data are lacking 
regarding the change in DII over longer periods of time. We assessed changes in the DII 
among women in the Women’s Health Initiative (WHI). Methods: The DII was 
calculated using data from repeated food frequency questionnaires in the WHI 
Observational Study (OS; n=76,671) at baseline and Year 3, and in the Dietary 
Modification Trial (DMT; n=48,482) at 11 time points. Univariate generalized estimating 
equations were used to compare mean DII changes over time, adjusting for multiple 
comparisons. Multivariable linear regression models were used to determine predictors of 
DII change. Results: In the OS, mean DII decreased from -1.14 at baseline to -1.50 at 
Year 3. In the DMT, DII decreased from -0.40 to -1.70 in the intervention arm and from  
-0.38to -1.04 in the control arm from baseline to Year 3. These changes were influenced 
by BMI, education, and race/ethnicity. A prediction model explained ≈22% of the 
variance in the change in DII scores in the OS. Conclusion: In this population of 
postmenopausal women, dietary inflammatory potential was relatively stable in OS 
participants, but decreased significantly over time in women enrolled in the DMT. DII 
changes were modified by BMI, education, and race/ethnicity. Future research is 
warranted to examine whether reductions in DII over time are associated with decreased 
chronic disease risk.  





Dietary index or pattern analysis can produce more intuitively appealing results 
that may improve prediction of disease risk as compared to examining individual foods or 
nutrients separately.
4,23,24,26
 Despite the growing use of dietary index or pattern 
analysis,
28-30
 relatively few studies have investigated the stability of dietary indices or 
patterns over time,
31-37
 or the factors influencing such stability.
269-271
 To the best of our 
knowledge, this evaluation has not been conducted in relation to the inflammatory 
potential of diet.  
Dietary behaviors are subject to change over time,
34,35
 and  mainly influence 
chronic disease outcomes when they persist over time.
31
 Knowledge of the longitudinal 
stability of dietary patterns could aid researchers in planning follow-up measurements or, 
as Weismayer et al. indicated,
34
 the cost of maintaining such cohorts could be reduced if 
diet is proven to be stable over time (e.g., by reducing the necessity for frequent data 
collection).  




 based on 
the evidence that many dietary factors have anti- or pro-inflammatory properties and the 
idea that no nutrient or food is consumed alone but in conjunction with other nutrients. In 
the current study, we calculated the DII based on the food frequency questionnaires 
(FFQ) used in the Women’s Health Initiative (WHI) Observational Study (OS) and 
Dietary Modification Trial (DMT). Our goal was to examine the stability of the 
inflammatory potential of diet, and the predictors of change in dietary inflammatory 
potential over time. We compared dietary behaviour change in an observational cohort of 





The design of the WHI has been described in detail elsewhere.
40
 The WHI began 
in 1992, spanning across 40 sites in the United States, and enrolled a total of 161808 
women between 1993 and 1998 and included full-scale randomized controlled trials, with 
ongoing follow-up. We used data up to September 30, 2010 for this investigation. The 
women were enrolled into the OS (n=93676) or Clinical Trials (CT, n=68132), with one 
of the CTs being the DMT (n=48835). Other components of the CT  included hormone 
therapy and calcium and vitamin D.
265
 The three CT components were overlapping, with 
some participants simultaneously recruited into more than one trial.
40
  
Exclusion criteria included any medical condition associated with a predicted 
survival of <3 years, alcoholism, other drug dependency, mental illness (e.g., major 
depressive disorder), dementia, not likely to live in the area for ≥3 years, and active 
participation in another intervention trial. Women were further excluded from the DMT if 
their diets were assessed to have <32% energy from fat.
266
 Demographic information and 
dietary data were obtained by self-report using standardized questionnaires, and certified 
staff performed physical measurements. The WHI protocol was approved by the 
institutional review boards at the Clinical Coordinating Center at the Fred Hutchinson 
Cancer Research Center (Seattle, WA) and at each of the 40 Clinical Centers.
14
  
4.3.2 Dietary Assessment 
Figure 4.1 describes the administration of FFQs in the WHI OS and DMT. During 
screening for the WHI, all participants completed a baseline FFQ. Follow-up measures 
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included: an FFQ completed by all DMT participants in Year 1; an FFQ completed 
annually from Year 2 until study end (approximately ten years) in a random third of 
DMT participants; and an FFQ completed at Year 3 for ≈90% of OS participants. There 
was an average of two FFQs per participant in the OS and three FFQs per participant in 
the DMT. The 122-item WHI FFQ line item nutrient data was obtained from the 
University of Minnesota’s Nutrient Data system for research (NDSR) version 4.03_31 
software,
272
 which is based on the US Department of Agriculture Standard Reference 
Releases and manufacturer information. The WHI FFQ has shown comparable results 
with 24-hour dietary recall interviews and food records in the WHI.
266
  
4.3.3 Description of the DII (outcome of interest) 





 of the DII have been described elsewhere. Briefly, an 
extensive literature search was performed to obtain peer-reviewed journal articles that 
examined the association between six inflammatory biomarkers (IL-1, IL-4, IL-6, IL-10, 
TNFα, and CRP) and 45 specific foods and nutrients (components of the DII).  Scores 
were derived and standardized to a representative global diet database constructed based 
on 11 datasets from diverse populations in different parts of the world. Overall DII scores 
for each individual represent the sum of each of the DII components in relation to the 
comparison database.
38
 The DII score characterizes individuals’ diets on a continuum 
from maximally anti-inflammatory to maximally pro-inflammatory, with higher DII 
scores indicating more pro-inflammatory diets, while lower scores indicate more anti-
inflammatory diets. In the WHI FFQ, 32 of the 45 original DII components were 
available for inclusion in the overall DII score. Components such as ginger, turmeric, 
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garlic, oregano, pepper, rosemary, eugenol, saffron, flavan-3-ol, flavones, flavonols, 
flavonones, anthocyanidins that are included in the original DII calculation
38
 were not 
included in the current study because they were not assessed in the WHI FFQ. 
4.3.4 Statistical analysis 
Participants with reported total energy intake judged to be implausible 





) (n=2,051) as well as those with only one FFQ (n=1,5479) or 
missing FFQ (n=32), were excluded from the current study, leaving 76,671 in the OS and 
46,482 in the DMT for the final analyses (Figure 1). Frequencies and percentages were 
calculated to describe baseline characteristics of participants. We computed mean DII 
scores at baseline and Year 3 in the OS and at 11 different time points between baseline 
and Year 10 inclusive in the DMT; and used these to describe changes over time in the 
OS, or plotted DII scores on graphs for a visual appraisal of the longitudinal trend, 
separately for the intervention and control arms of the DMT. Analyses were stratified by 
BMI, education, and race/ethnicity. To determine significant differences between mean 
DII scores calculated at different time points, we constructed marginal linear regression 
models using generalized estimating equations (GEE) that adjusted for within-subject 
correlation in the DII measurements, in order to calculate and compare all pair-wise 
contrast estimates between mean DII scores. The GEE model was a univariate model 
with time from baseline as the only independent variable and changes in the DII over 
time as the dependent variable, adjusted for multiple comparisons using the Bonferroni 
approach, and stratified in the DMT by intervention arm.  
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Next, we utilized stepwise linear regression to construct the most parsimonious 
predictive multivariable model for change in DII from baseline to Year 3 in the OS. A 
previous WHI study (Tinker et al.,2007) investigated predictors of dietary change and 
maintenance in the DMT and included intrapersonal, interpersonal, intervention 
characteristics and clinical center characteristics as predictors 
269
. The DMT intervention 
moved participants toward an anti-inflammatory diet; therefore, predictors of dietary 
change investigated by Tinker et al are likely to predict DII change in the DMT. We 
therefore focused mainly on the potential predictors of DII change in the OS. We 
included the following baseline variables in the stepwise regression model:  baseline DII, 
age group, BMI, race/ethnicity, educational level, physical activity, history of diabetes, 
hypertension, arthritis, cancer, use of non-steroidal anti-inflammatory drugs (NSAIDs), 
statins, anti-depressants, unopposed estrogen use, combined estrogen and progesterone 
use (Table 4.1 presents categories of potential predictors). The entry criterion into the 
stepwise linear regression model was P <0.10, while the exit criterion was P >0.10. The 
stepwise model identified variables that were included in a multivariable linear regression 
model to calculate beta (β) coefficients, corresponding p-values, and the R
2 
for the overall 
predictive model. Participants with missing data in the predictors (n=3,438) were further 
excluded, leaving a final sample of 73,233 OS participants for the prediction model.  
Analyses were conducted using SAS
®
 version 9.3 (SAS Institute). All tests were 
2-sided and p<0.05 was used to assess statistical significance of parameter estimates.  
4.4 Results 
Participant characteristics were similar between OS and DMT for many covariates 
including race/ethnicity, educational level, smoking status, arthritis, unopposed estrogen 
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use, and combined estrogen and progesterone use (Table 4.1). More OS (23.8%) than 
DMT (16.7%) participants were ≥70 years; a higher proportion of participants in the 
DMT (38.4%) than OS (25.4%) were obese; and the proportion of individuals with a 
previous cancer diagnosis reported at baseline, was about three times higher in the OS 
(12.8%) than in the DMT (4.4%), likely due to cancer survivors joining the WHI but 
being excluded from the DMT (Table 4.1).   
In the OS, the mean (±SD) overall DII decreased from -1.14 (±2.58) at baseline to 
-1.50 (±2.60) at Year 3. Corresponding averages for the DMT intervention arm were -
0.40 (±2.54) and -1.70 (±2.63); and for the control arm, -0.38 (±2.55) and -1.04 (±2.60) 
(Figure 4.2) (all p-values for between-group differences across time were <0.0001). Mean 
DII scores at baseline were significantly different than at all other time points in both the 
intervention and control arms, as shown in the Bonferroni-adjusted p-values for all pair-
wise comparisons in Table 4.2.  
There was evidence for interaction between DII change and BMI, education, and 
race/ethnicity; so, analyses were further stratified by these variables in the OS and DMT. 
In the OS, normal-weight women experienced the largest decrease in DII between 
baseline and Year 3 [-1.39 (±2.55) to -1.81 (±2.54)] compared to obese women [-0.78 
(±2.61) to -1.04 (±2.67)]; while women with at least some college education showed the 
greatest change in DII [-1.39 (±2.51) to -1.77 (±2.52)] compared to women with less than 
a high school education, whose DII scores were more pro-inflammatory [0.26 (±2.71) to 
0.06 (±2.71)]. In terms of race/ethnicity, Asians/Pacific Islanders (A/PI) experienced the 
largest change in DII [-1.76 (±2.53) to -2.04 (±2.51)], followed by European Americans 
 
72 
(EA) [-1.25 (±2.52) to -1.63 (±2.53)]. African Americans (AA) and Hispanics (HP) had 
more pro-inflammatory DII scores.  
Figures 4.3, 4.4 and 4.5 present the corresponding longitudinal trends in the DMT 
intervention and control arms, which parallel those in the OS upon stratification by BMI, 
education, and race/ethnicity; though DII changes in the intervention arm were greater 
than in the control arm. Normal-weight women consistently experienced the largest DII 
decrease over time, followed by overweight women, while obese women showed the 
smallest decrease in DII over time (Figure 4.3). Highly educated women experienced the 
most anti-inflammatory changes over time (Figure 4.4).  A/PI showed the largest DII 
decreases over time, while AA and HP showed the smallest changes over time (Figure 
4.5). 
The final predictive model presented in Table 4.3 explained 22% of the variance 
in DII changes between baseline and Year 3 in the OS. Decreases in DII over time were 
predicted by baseline DII (having a higher baseline DII predicted a larger decrease in 
DII), being A/PI or EA, having BMI<25kg/m
2
, being more educated, being a nonsmoker, 
and meeting public health recommendations for physical activity.  
4.5 Discussion 
Using data from both the WHI OS and DMT, we described changes over time in 
the inflammatory potential of diet using the DII. The DII score in the OS remained 
relatively stable from baseline to Year 3, with an average change of -0.36 ± 2.35, 
representing about 2% of the full range of change in DII scores (-9.52 to 10.71). We 
demonstrated that the DII decreased substantially from baseline to Year 1 in the DMT 
intervention arm, achieving the lowest mean score in Year 3, and then increasing 
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gradually until study end. The longitudinal trend of DII changes was similar in both arms 
of the DMT; however, changes in the intervention arm were almost double those 
observed in the control arm during the first five years of follow-up. In both the OS and 
DMT, participants who experienced the largest DII decrease had a normal BMI, a high 
educational level, and were A/PI or EA. Those who experienced the smallest decrease 
were obese, had less than high school education, and were HP or AA.  
OS participants may have started the study consuming foods with lower mean 
inflammatory potential compared to DMT participants, likely due to DMT eligibility that 
required women to consume diets with ≥32% energy from fat.
40,266
 This requirement had 
the effect of producing higher DII scores (i.e., more pro-inflammatory) at baseline for 
DMT participants because fat is a strongly pro-inflammatory component of the DII 
38
. It 
also could help explain reductions in the DII among DMT participants, who needed to 
meet a dietary fat entry criterion.
273
 
Highly educated women could be more heavily exposed to information about 
healthier food choices and have better financial access to a wider variety of healthier food 
choices than women with lower educational levels. In a study on the longitudinal trends 
in diet over a 20-year period, diet quality improved with higher educational attainment.
274
 
Chaix et al. observed that poorly educated participants shopping in specific supermarket 
brands and in supermarkets whose catchment areas included more poorly educated 
residents had higher BMIs or waist circumferences.
275
 Additionally, Drewnowski et al. 
found lower levels of education and incomes, among other factors, to be consistently 
associated with higher obesity risk.
276
 These findings could partially explain our result 
showing that obese and less-educated participants experienced the smallest decreases in 
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DII. The low DII scores in A/PI and EA compared to other race/ethnic groups may be 
due to different dietary patterns inherent in the cultures of the racial/ethnic groups. For 
example, diets of most Asian populations contain numerous anti-inflammatory 
constituents and lack many of the pro-inflammatory substances in Western diets.
277,278
 In 
the WHI, EA women are relatively better educated
279
 and may be more willing to change 
their diets in keeping with recommendations.
276
 
While the slight decrease in the dietary inflammatory potential from baseline to 
Year 3 in participants in the OS, provided insights into changes in dietary behavior over 
time, the follow-up period was insufficient to draw conclusions regarding long-term 
changes in dietary behavior in an observational setting. Participants in the control arm of 
the DMT were not asked to make dietary changes and were observed throughout the 10-
year follow-up period; however, the trend in dietary behavior change over time in this 
group was similar, though smaller, to that observed in the intervention arm. Participants 
randomized to the control arm may have been motivated to change their diets prior to 
joining the study, and thus made personal efforts to improve their diets over time. 
Some studies have examined the stability of dietary patterns over time;
31-37
 
however, to the best of our knowledge, this is the first to study the stability of a dietary 
index describing the inflammatory potential over time. Previous studies reported 
inconsistent results on the stability of dietary behaviors over time, with some indicating 
stable behaviors after a short follow-up period of about 2 to 4 years,
33,37
 and others 
reporting significant changes only after a moderately long follow up (e.g., ≥7 years).
34,36
 
Changes in diet over time may be due, in part, to the response to frequent updates to 
dietary guidelines, changes over time in the availability of different foods in some 
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communities, and disease diagnosis that may alter dietary intake (e.g., diabetes or 
hypertension). Methodologic differences between studies would include differences in 
duration of follow-up, frequency and method of diet assessment, and sample composition 
and size. 
This study has several strengths including the relatively large population-based 
sample in the OS and DMT, good regional and racial/ethnic representation, and inclusion 
of large number of potential predictors of DII change. The DMT had a relatively long 
follow-up duration with diet assessed annually on random subsamples of the study 
population. Our study also had some limitations: FFQ data were not available in the OS 
after Year 3; thus we were not able to compare dietary behavior change between the OS 
and DMT beyond the first three years of follow up. The decrease in dietary inflammatory 
potential in the first three years may have been due to survey learning effects, in part 
attributed to social desirability bias, rather than a real improvement in diet quality. This 
limitation might have been mitigated had social desirability, an established source of bias 
of dietary self-report data, been measured in the WHI.
280,281
 In our DMT sample, not 
every participant had FFQ data at all 11 time points, which could have reduced the effect 
of survey learning as participants did not complete the FFQ every year. Sample sizes 
from Year 8 to 10 were very small and may not be representative of the entire DMT 
population. Although WHI enrolled only postmenopausal women, average DII scores in 
the WHI were comparable to other US populations that have been examined.
39,282
 
After including a comprehensive list of demographic, lifestyle and health-related 
factors, our final prediction model explained 22% of the variation in DII change in the 
OS. This represents reasonable explanatory ability when one considers that a change 
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score is accompanied by large overall variance owing to the fact that the variance of a 
difference is the sum of the variance of the individual components
283
 (while the absolute 
difference can often be quite small). Other potential predictors of DII change that are 
outside the scope of the current study may include behavioural factors, such as those 




4.6 Conclusion  
In this population of postmenopausal women, the average DII was relatively 
stable in the OS from baseline to Year 3, but decreased significantly over time in a 
manner consistent with improved anti-inflammatory potential, achieving its lowest mean 
value at Year 3 in DMT intervention participants and, to a smaller extent, among control 
arm participants. In all three study groups, the extent of decrease was influenced by BMI, 
education, and race/ethnicity. Baseline DII and several demographic, lifestyle and clinical 
factors significantly predicted changes in the inflammatory potential of diet in the first 
three years of follow up in an observational setting. Future research is warranted to 

















Figure 4.1. Participant flow in the administration of food frequency questionnaires in the Women’s Health Initiative (WHI) 
Observational Study (OS) and Dietary Modification Trial (DMT), 1993-2010 




93,676 participants in the OS 
76,671 included in analyses 
(after excluding 1,785 due to 
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values, 23 missing FFQs, 
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46,482 included in analyses (after excluding 11 due to implausible total 
energy values, 9 missing FFQs, 711 due to extreme BMI values and 1,622 
due to single FFQ,) 
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Age groups (years) 
   
<50-59 24144 (31.5) 6832 (36.7) 10203 (36.6) 
60-69 34293 (44.7) 8681 (46.7) 13033 (46.7) 
70-79 18234 (23.8) 3091 (16.6) 4642 (16.7) 
Body mass index (kg/m
2
) 
   
Normal ( <25) 30577 (39.9) 5230 (28.1) 6820 (24.5) 
Overweight (25.0 - <30) 26605 (34.7) 6534 (35.1) 9940 (35.7) 
Obese (≥30) 19489 (25.4) 6840 (36.8) 11118 (39.9) 
Race/ethnicity 
   
Asian or Pacific Islander 2102 (2.7) 421 (2.3) 645 (2.3) 
African American 4697 (6.1) 1932 (10.4) 2836 (10.2) 
Hispanic/Latino 2253 (3.0) 661 (3.6) 999 (3.6) 
European American  66331 (86.8) 15263 (82.2) 22916 (82.3) 
Other 1078 (1.4) 286 (1.5) 430 (1.6) 
Educational level 
   
Less than high school 814 (1.1) 186 (1.0) 332 (1.2) 
Some high school/GED 21209 (27.9) 5703 (30.8) 8609 (31.1) 
Some years of 
college/graduate 
54067 (71.0) 12604 (68.2) 18761 (67.7) 
Smoking status 
   
Never 38661 (50.1) 9502 (51.7) 14386 (52.1) 
Former 32813 (43.3) 7715 (50.0) 11370 (41.2) 
Current 4242 (5.6) 1169 (6.3) 1842 (6.7) 
Physical activity (PA), minutes/week 
  
Not meeting PA 
recommendations 
39636 (52.2) 10860 (65.2) 16421 (65.7) 
Meeting PA 
recommendations 
36254 (47.8) 5797 (34.8) 8567 (34.3) 
Diabetes 
   
No 66796 (87.1) 15450 (83.1) 22952 (82.3) 
Yes 9875 (12.9) 3154 (16.9) 4926 (17.7) 
Hypertension 
   
No 51266 (68.0) 10811 (65.5) 15974 (64.5) 
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Yes 24147 (32.0) 5704 (34.5) 8794 (35.5) 
Arthritis 
   
No 39324 (51.6) 10042 (54.5) 14989 (54.3) 
Yes 36845 (48.4) 8371 (45.5) 12596 (45.7) 
Cancer 
   
No 66375 (87.2) 17613 (95.6 26382 (95.6) 
Yes 9757 (12.8) 809 (4.4) 1210 (4.4) 
Duration of estrogen use by category 
  
None 47756 (62.3) 11648 (62.6) 17496 (62.8) 
<5 Years 9785 (12.7) 2573 (13.8) 3748 (13.4) 
5 to <10 Years 5808 (7.6) 1368 (7.4) 2086 (7.5) 
10 to <15 Years 4609 (6.0) 1102 (5.9) 1685 (6.0) 
15+ Years 8711 (11.4) 1911 (10.3) 2863 (10.3) 
Duration of estrogen & progesterone use by category 
 
None 53804 (70.2) 13431 (72.2) 20195 (72.4) 
<5 Years 10943 (14.3) 2671 (14.4) 3934 (14.1) 
5 to <10 Years 6392 (8.3) 1388 (7.4) 2162 (7.8) 
10 to <15 Years 37228 (4.9) 749 (4.0) 1103 (4.0) 
15+ Years 1808 (2.3) 362 (2.0) 484 (1.7) 
Statin use 
   
No 64049 (83.5) 13937 (74.9) 20601 (73.9) 
Yes 12622 (16.5) 4667 (25.1) 7277 (26.1) 
Antidepressant use 
   
No 67557 (88.1) 15502 (83.3) 23144 (83.0) 
Yes 9114 (11.9) 3102 (16.7) 4734 (17.0) 
NSAIDs use 
   
No 36819 (48.0) 6687 (35.9) 9732 (34.9) 
Yes 39852 (52.0) 11917 (64.1) 18146 (65.1) 








Figure 4.2. Average dietary inflammatory index (DII)
1
 scores across years of follow-up in 





(P-value for the difference in DII scores between intervention and control was 0.62 at 
baseline, and <0.0001 for each year from year 1 onwards) 
2
Numbers of participants (Intervention: 19470, 18061, 6081, 3255, 5071, 5835, 7160, 
4641, 2734, 1578, and 417; Control:  29216, 26753, 8882, 4922, 7902, 9028, 10860, 
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Table 4.2. Bonferroni-adjusted p-values of all pair-wise comparisons of the mean dietary inflammatory index scores across years of 





























<0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
1 (25749) <0.0001 
 
<0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.01 0.0004 0.99 0.99 
2   (8524) <0.0001 <0.0001 
 
0.11 0.99 0.99 0.99 0.99 0.99 0.99 0.99 
3   (4717) <0.0001 <0.0001 0.23 
 
0.99 0.99 0.01 0.001 0.99 0.004 0.61 
4   (7553) <0.0001 <0.0001 0.68 0.99 
 
0.99 0.22 0.01 0.99 0.04 0.99 
5  (10375) <0.0001 <0.0001 0.0003 0.99 0.99 
 
0.52 0.03 0.99 0.05 0.99 
6   (8634) <0.0001 <0.0001 0.01 0.99 0.99 0.99 
 
0.99 0.99 0.99 0.99 
7   (6918) <0.0001 <0.0001 0.0002 0.99 0.99 0.99 0.99 
 
0.99 0.99 0.99 
8   (4240) <0.0001 <0.0001 <0.0001 0.09 0.003 0.33 0.04 0.99 
 
0.99 0.99 
9   (2244) <0.0001 <0.0001 0.99 0.99 0.99 0.99 0.99 0.99 0.14 
 
0.99 
10     (600) 0.0004 0.99 0.99 0.99 0.99 0.99 0.99 0.99 0.24 0.99 
 
























Figure 4.3. Average dietary inflammatory index over time by body mass index category and Dietary Modification Trial arm; Women's 
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Figure 4.4. Average dietary inflammatory index (DII) over time by educational level and Dietary Modification Trial arm; Women's 
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Table 4.3. Multivariable predictive model of change in dietary inflammatory index over 
time in the Observational Study; Women's Health Initiative, 1993-2010 
 
Predictors β (SE) P-value (β) 
Baseline DII -0.44 (0.00) <0.0001 




Normal weight (>25) referent 
 
Overweight(25 - <30) 0.25 (0.02) <0.0001 
Obese(>30) 0.10 (0.02) <0.0001 
Race/ethnicity 
  European American  referent 
 
African American 0.48 (0.03) <0.0001 
Asian or Pacific Islander -0.17 (0.05) <0.0001 
Hispanic 0.68 (0.05) <0.0001 
Other 0.07 (0.06) 0.28 
Educational level 
  
Some college/graduate referent 
 
Some high school/GED 0.31 (0.02) <0.0001 
Less than high school 0.47 (0.10) <0.0001 
Use of NSAIDs 
  Yes referent 
 No 0.08 (0.01) <0.0001 




60-69 -0.04 (0.01) <0.0001 
70-79 0.02 (0.01) 0.18 
Physical activity (minutes/week) 
  
Meeting PA recommendation referent 
 








Former -0.07 (0.02) <0.0001 
Current 0.24 (0.03) <0.0001 
Hypertension status 
  No referent 
 
Yes 0.06 (0.01) <0.0001 
Diabetes 
  No referent 
 
Yes 0.10 (0.02) <0.0001 
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Use of estrogen & progesterone 
  None referent 
 
< 5y 0.00 (0.02) 0.91 
5 to <10y -0.10 (0.02) 0.0001 
10 to <15y -0.09 (0.02) 0.0002 
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5.1 Abstract  
Introduction: To evaluate changes in the inflammatory potential of diet and 
subsequent risk of colorectal cancer (CRC), we used the dietary inflammatory index 
(DII), to predict newly incident CRC in the Women’s Health Initiative (WHI). Methods: 
Data were obtained from 110,665 postmenopausal women recruited from 1993-1998 into 
the WHI and followed through September 30, 2010. Food frequency questionnaires data 
were used to compute cumulative average DII scores that were then used in Cox 
proportional hazards (PH) models to estimate hazard ratios (HR) and 95% confidence 
intervals (95%CI) for newly incident CRC. Patterns in DII change from baseline to Year 
3 were computed in a subset of 79,484 women, from which HR were calculated using 
Cox PH models. Results: HR for the association between high DII scores and CRC were 
consistently significantly elevated in the first seven years of follow up, for colon cancer 
with multivariable-adjusted HR ranging from 1.30 in Year 2 to 1.58 in Year 7, comparing 
the highest with the lowest quintile. No significant associations were observed between 
cumulative average DII and rectal cancer. Compared to participants in the anti-
inflammatory stable category, risk was increased in participants with a pro-inflammatory 
stable diet, for CRC (HR, 1.18; 95%CI, 0.99, 1.41), and for rectal cancer (HR, 1.53; 
95%CI, 1.01, 2.32). Conclusion: A history of long-term pro-inflammatory diets increases 
the risk of colon cancer while shorter-term stable pro-inflammatory diets, increase the 
risk of rectal cancer. Lowering the inflammatory potential of diet could be a means for 
colon cancer, and potentially rectal cancer prevention. 
Key words: changes in dietary inflammatory potential, colorectal cancer, dietary 




Colorectal cancer is the third most commonly diagnosed cancer in American 
women after lung and breast cancers.
173
 The etiology of colorectal cancer involves a 
complex interaction of cellular and molecular processes with environmental factors. Of 
these factors, dietary patterns that modulate inflammation
48-50
 may be important, given 
the central role of inflammation in the carcinogenesis process.
79
 The American Institute 
for Cancer Research estimates that half of colorectal cancers can be prevented by 
adopting healthy lifestyle behaviors including healthy dietary patterns.
174
 Dietary 
patterns, or dietary indices that take into account multiple dietary factors, can provide a 
more comprehensive assessment of diet and may be more predictive of disease processes 
and outcomes than single nutrients or foods.
23,26
  
Most dietary patterns derived through data-driven approaches or index-based 
methods have been shown to be associated with colorectal cancer risk.
28,30,176,177,180
 
However, these findings are often heterogeneous by anatomic subsite of colorectal 
cancer. We previously reported that a more pro-inflammatory diet as measured by the 
dietary inflammatory index (DII)
38,39
 was associated with increased risk of colorectal 
cancer using baseline food frequency questionnaire data in the Women’s Health Initiative 
(WHI), and that the association was more pronounced for colon cancer than for rectal 
cancer (Tabung FK, Steck SE, Ma Y, et al., unpublished data, 2014).  
Despite the growing interest in the role of dietary patterns in colorectal cancer 
risk,
28,30,176,177,180
 most studies have examined dietary patterns at one point in time only. 
However, dietary behaviors mainly influence chronic disease outcomes when they persist 
for a longer period of time.
31
 We have shown that DII scores decreased significantly in 
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women enrolled in the WHI Dietary Modification Trial. The longitudinal trend in DII 
scores was similar to that of percent fat reduction over time (Tabung FK, Steck SE, 
Zhang J, et al., unpublished data, 2014). Risk of colorectal cancer is believed to 
accumulate over time, thus, dietary changes over time may have a greater impact on 
colorectal cancer risk compared with diet assessed at only one point in time. In the 
current study, our objective is to evaluate the role of both the cumulative history, and the 
changes in the inflammatory potential of diet over time, on colorectal cancer risk. 
5.3 Methods 
5.3.1 Study population 
The WHI study is a large and complex clinical investigation of strategies for the 
prevention and control of some of the most common causes of morbidity and mortality 
among postmenopausal women. The design of the WHI has been described in detail 
elsewhere.
40
 Briefly, the WHI began in 1992, implemented in 40 sites across the United 
States, and enrolled a total of 161,808 women between 1993 and 1998. The WHI enrolled 
93,676 women into an Observational Study (OS) and 68,132 participants into Clinical 
Trials (CT), with an average of 11.3 years of follow-up until September 30, 2010.
265
 The 
CTs included three components: Hormone Therapy, Calcium and Vitamin D, and the 
Dietary Modification Trial (DMT). For the DMT, women were randomly assigned to a 
usual-diet comparison group (n=29,294) or an intervention group (n=19,541) with a 20% 
low-fat dietary pattern with increased vegetables, fruits, and whole grains. Women who 
proved to be ineligible for, or who were unwilling to enroll in the CT components were 





Exclusion criteria for both the OS and CT included any medical condition 
associated with a predicted survival of less than three years, alcoholism, other drug 
dependency, mental illness (e.g., major depressive disorder), dementia, active 
participation in another intervention trial and not likely to live in the area for at least 3 
years. Demographic information and dietary data were obtained by self-report using 
standardized questionnaires. Certified staff performed physical measurements, including 
blood pressure, height and weight, and blood samples at the baseline clinic visit. Women 
were further excluded from the DMT if their diets were assessed to have <32% energy 
from fat.
266
 The WHI protocol was approved by the institutional review boards at the 
Clinical Coordinating Center (CCC) at the Fred Hutchinson Cancer Research Center 
(Seattle, WA) and at each of the 40 Clinical Centers.
14
   
5.3.2 Diet assessment 
Figure 5.1 describes the administration of food frequency questionnaires (FFQ) in 
the WHI. During screening for the WHI, all participants completed a baseline FFQ. At 
follow-up, the FFQ was completed at Year 3 for ≈90% of OS participants. About 92% of 
DMT participants completed an FFQ in Year 1, and a random third of participants were 
invited to complete an FFQ annually from Year 2 until study end (approximately ten 
years) (Figure 5.1). There was an average of two FFQs per participant in the OS and three 
FFQs per participant in the DMT. The 122-item WHI FFQ line-item nutrient data was 
obtained from the University of Minnesota’s Nutrient Data system for research (NDSR) 
version 4.03_31 software,
272
 which is based on the US Department of Agriculture 
Standard Reference Releases and manufacturer information. The WHI FFQ has shown 





5.3.3 The dietary inflammatory index (DII) 




 of the DII have been described 
elsewhere. Briefly, an extensive literature search was performed to obtain peer-reviewed 
journal articles that examined the association between six well known inflammatory 
biomarkers (IL-1β, IL-4, IL-6, IL-10, TNFα, and CRP) and 45 specific foods and 
nutrients (components of the DII).  Scores were derived and standardized to a 
representative global diet database constructed based on 11 datasets from diverse 
populations in different parts of the world.  Overall DII scores for each individual 
participant represent the sum of each of the DII components in relation to the comparison 
global diet database.
38
 The DII score characterizes an individual’s diet on a continuum 
from maximally anti-inflammatory to maximally pro-inflammatory, with a higher DII 
score indicating a more pro-inflammatory diet and a lower (i.e., more negative) DII score 
indicating a more anti-inflammatory diet.  In the WHI FFQ, 32 of the 45 original DII 
components were available for inclusion in the overall DII score (see
38
 for list of 45 DII 
components). Components such as ginger, turmeric, garlic, oregano, pepper, rosemary, 
eugenol, saffron, flavan-3-ol, flavones, flavonols, flavonones, anthocyanidins that are 
included in the original DII calculation
38
 were not included in the current study because 
they were not  available from the WHI FFQ.  
5.3.4 Outcomes assessment 
The WHI outcomes ascertainment and adjudication methods have been previously 
described.
267
 Briefly, participants (or next-of-kin) self-reported cancer diagnoses reported 
on questionnaires annually in the OS or semiannually in the CT through 2005 and 
 
93 
annually in all thereafter. Colorectal cancer events reported were verified by centrally 
trained physician adjudicators after review of medical records and pathology reports.  
 The outcome for these analyses was colorectal cancer, including cancers of the 
colon and rectum (including rectum and rectosigmoid).  Proximal colon cancers were 
defined as cancers of the cecum, ascending colon, right colon, hepatic flexure of colon, 
and transverse colon (ICD=C18.0, C18.2-18.4), and distal colon cancers were defined as 
cancers of the splenic flexure of colon, descending colon, left colon and sigmoid colon 
(ICD=C18.5-18.7). Survival time was defined as days from enrollment or randomization 
until colorectal cancer diagnosis while censoring time was defined as days from 
enrollment or randomization until death or last contact occurring on or before September 
30, 2010, in participants without colorectal cancer.  
5.3.5 Statistical analysis 
We utilized data from 142,511 women participating in the WHI OS and DMT. 
Exclusion criteria included: women with colorectal cancer at baseline or missing 
colorectal cancer status at baseline (n=2,272), women with reported total energy intake 
values judged to be implausible (≤600 kcal/day or ≥5000 kcal/day) (n=1,796) or extreme 
BMI values (<15kg/m
2
 or > 50kg/m
2
) (n=2,014), as well as women with single FFQs 
(n=15,122) or missing FFQs (n=32) (Figure 5.1). Additionally, we excluded participants 
with missing data in the covariates (n=10,610), leaving a total of 110,665 participants for 
these analyses (72,261 in OS and 38,404 in DMT). Frequencies and percentages were 
computed to describe the distribution of covariates across quintiles of cumulative average 
DII for the DII assessed from baseline to Year 3. 
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To determine the role of cumulative history of the inflammatory potential of diet 
in colorectal cancer risk over time, we calculated ten cumulative averages of DII 
incrementally starting from the average between baseline and year one DII.
172
 The 
cumulative average was then categorized into quintiles, and used to estimate hazard ratios 
(HR) for newly incident overall colorectal, colon, and rectal cancers, using multivariable-
adjusted Cox regression models  Colorectal cancers diagnosed prior to year one were 
excluded from the models. This approach was repeated for the average DII of baseline, 
year one, and year two, with colorectal cancer cases diagnosed prior to year two excluded 
to avoid the possibility of change in diet due to subclinical disease and to ensure that only 
participants at risk of developing colorectal cancer going forward, were included in the 
models. This approach was repeated until DII estimates at all ten time points were 
used.
172
 We categorized the cumulative average DII into quintiles, used these to calculate 
HRs and then plotted the HRs on graphs for a visual appraisal of the longitudinal trend in 
risk, separately for colon and rectal cancers in the DMT. 
To determine the role of changes in patterns of the inflammatory potential of diet 
over time in colorectal cancer risk, we calculated the DII from baseline and year 3 FFQs 
administered to 79,484 women in the OS and DMT. We categorized the DII at both time 
points into quintiles (Q) and further categorized changes in the inflammatory potential of 
diet based on quintile differences between baseline and year 3, as follows:  
1. Anti-inflammatory stable: Q1 or Q2 at both time points or change from Q3 to Q2;  
2. Anti-inflammatory change: changes ≤ -2Q;  
3. Neutral inflammation stable: changes from Q2 to Q3, Q4 to Q3 or stable at Q3 at 
both time points;  
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4. Pro-inflammatory change: changes ≥ 2Q;  
5. Pro-inflammatory stable: Q4 or Q5 at both time points, or change from Q3 to Q4.  
The names given to these categories of DII changes were meant to be qualitative 
only. Next, Cox proportional hazards regression models were used to estimate HR and 
associated 95%CI for colorectal, colon (proximal/distal), and rectal cancer incidence, by 
patterns of DII changes, with adjustment for multiple covariates. The anti-inflammatory 
stable category, considered to be the healthiest category, was the referent for all models. 
Potential confounders that changed HRs by >10% were retained in the final model 
and included: age group (years) (50-59, 60-69, 70-79); race/ethnicity, European 
American (EA), African American (AA), Hispanic (HP), Asian or Pacific Islander 
(A/PI), and other race groups (other); educational levels (less than high school, some high 
school /GED, at least some college/graduate education); smoking status (current, past, 
never); body mass index [BMI= weight(kg)/height(m)
2





), and obese (≥30kg/m
2
)); physical activity (PA) was 
categorized based on public health recommendations,
284
 as meeting or not meeting PA 
recommendations (≥150 minutes/week of moderate intensity PA or ≥75 minutes/week of 
vigorous intensity PA versus<150 minutes/week of moderate intensity PA or <75 
minutes/week of vigorous intensity PA, respectively); history of diabetes (yes/no), 
hypertension (yes/no), arthritis (yes/no); non-steroidal anti-inflammatory drug (NSAID) 
use (yes/no); category and duration of estrogen use and category and duration of 
combined estrogen and progesterone use both categorized into five groups (none, <5y, 5 
to <10y, 10 to <15y, and ≥15y). Data on potential confounders were collected by self-





Each covariate in the final models for both cumulative average DII and patterns of 
changes in DII was tested for proportional hazards using cumulative sums of Martingale-
based residuals. Age group, and smoking status violated the PH assumption and models 
were therefore stratified by these two covariates. We investigated effect modification of 
the association between cumulative average DII, and changes in the DII and colorectal 
cancer incidence by age, race/ethnicity, education, BMI and NSAID use, by including 
two-way cross-product terms for these covariates in the models, and assessed significant 
effect modification at p <0.05. None of the cross-product terms were significant and 
therefore no subgroup analyses were conducted. Statistical significance was determined 
by evaluating 95%CI. Statistical analyses were conducted using SAS
®
 version 9.3 (SAS 
Institute, Cary, NC), and all tests were two-sided. 
5.4 Results 
Table 5.1 shows the distribution of participants’ characteristics in quintiles of 
cumulative average DII from baseline to year 3. Proportions of most covariates differed 
between the quintiles. For example, there was a higher proportion of AA (15%), 
participants with < high school education (2%), current smokers (9%), and obese 
participants (37%), in the highest compared to the lowest quintile (Table 5.1). During an 
average 11.7 years of follow-up, 1,240 incident colorectal cancer cases (1,036 colon and 
219 rectal) were identified. 
Table 5.2 presents hazard ratios of the association between cumulative average 
DII and colorectal cancer. Comparing participants in the highest with the lowest quintile 
of DII, in Year 3 where OS participants had the only other diet assessment, the 
cumulative average DII was significantly associated with an increased risk of colorectal 
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cancer overall (HR, 1.33; 95%CI, 1.10, 1.61) and in subgroup analyses of OS participants 
(HR, 1.34; 95%CI, 1.05, 1.70) but not DMT participants (HR, 1.28; 95%CI, 0.95, 1.73). 
In all other years of follow-up, HR were indicative of a positive association in DMT 
participants but did not attain statistical significance.  
Figures 5.1 and 5.2 present HR and 95%CIs for colon and rectal cancers, 
respectively, at the various time points of cumulative diet assessment comparing DMT 
participants in the highest to the lowest cumulative average DII quintile. For colon 
cancer, risk was not significantly increased in Year 1, but from Year 2 to Year 7, risk was 
consistently significantly increased, and became attenuated from Year 7 to study end in 
Year 10 (Figure 5.1). We found no significant results for cumulative DII and rectal 
cancer (Figure 5.2).  
In the first 3 years of follow-up, 29.3% of participants were classified as having 
an anti-inflammatory stable pattern, 11.7% experienced anti-inflammatory change, 23.6% 
were in the neutral inflammation stable category, 12.1% experienced pro-inflammatory 
changes, while 23.3% were in the pro-inflammatory stable category. Table 5.3 presents 
the results of the associations between changes in the inflammatory potential of diet and 
colorectal cancer risk. Using participants in the anti-inflammatory stable category as the 
referent, rectal cancer risk was significantly increased in participants with a pro-
inflammatory stable diet (HR, 1.53; 95%CI, 1.01, 2.32). HR for colon cancer (HR, 1.11; 
95%CI, 0.91, 1.35) and overall colorectal cancer (HR, 1.18; 95%CI, 0.99, 1.41) were 




In this large prospective study, we demonstrated that:  1) a higher cumulative 
average score of the DII is associated with an increased risk of colorectal cancer 
especially colon cancer, while 2) a stable pro-inflammatory diet from baseline to year 3 
increased the risk of rectal cancer. To the best of our knowledge, this is the first study to 
characterize the association between the cumulative history, and changes over time in the 
inflammatory potential of diet, and risk of colorectal cancer. Given that FFQs were 
administered to OS participants at baseline and Year 3; a cumulative average DII could 
only be calculated for OS participants at Year 3, whereas analyses at all other time points 
included DMT participants. We selected these two time points for the analyses of 
changes in the DII over time, to include the maximum number of participants with FFQs 
(Figure 5.1). There was no statistically significant association between cumulative 
average DII and rectal cancer in the DMT, though a power calculation indicated that we 
could observe significant HR ranging from 1.13 to 1.47. There was however, a 
significantly higher risk of rectal cancer in models for changes in DII between baseline 
and Year 3 where analyses included subjects from both the OS and DMT.  
Our results are generally similar to previous findings from studies of diet quality 
and colorectal cancer risk,
28,145,202,285
 in terms of poorer diet quality (here characterized 
by higher, more pro-inflammatory DII scores) being associated with increased colorectal 
cancer risk. These other studies assessed diet quality at only one point in time. However, 
in a previous study we demonstrated that diet quality with respect to its inflammatory 
potential improves significantly over time in an interventional setting, though it is 
relatively stable in an observational setting (Tabung FK, Steck SE, Zhang J et al., 
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unpublished data, 2014). Risk of colorectal cancer is believed to accumulate over time; 
thus, dietary changes over time may have a greater impact on colorectal cancer risk 
compared with diet assessed at only one point in time.  
However, the relative stability of the dietary inflammatory potential in an 
observational setting could mean that diet assessment at any point in time during the 
study could be equally important in determining disease risk estimates. In the current 
study, we obtained a HR of 1.18 (95%CI, 0.99, 1.41) for the association between changes 
from baseline to Year 3 in the inflammatory potential of diet and colorectal cancer risk, 
comparing a stable pro-inflammatory change to an anti-inflammatory stable change, and 
a HR of 1.34 (95%CI, 1.05, 1.70) for the association between cumulative average DII and 
colorectal cancer risk from baseline to Year 3, comparing the highest and lowest quintiles 
of cumulative average DII in the OS. These risk estimates are similar to the HR of 1.22 
(95%CI, 1.05, 1.43) we obtained in a previous study, for the association between the 
dietary inflammatory potential at baseline only, and colorectal cancer risk (Tabung FK, 
Steck SE, Ma Y, et al., unpublished data, 2014).  
The link between inflammation and colorectal cancer is supported by findings 
from several studies showing either a reduced risk of colorectal cancer with regular use of 
NSAIDs,
83,84
 or a positive association between higher concentrations of inflammatory 
biomarkers and increased colorectal cancer risk.
89,113
 Other potential mechanisms through 
which a pro-inflammatory diet may increase risk of colorectal cancer include components 
of the metabolic syndrome, especially insulin resistance or glucose intolerance,
286-288
 and 
the microbiota. A high and sustained pro-inflammatory potential of the diet may 
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compromise the host-microbiota mutualism favoring the proliferation of toxic bacteria 
that have been suggested to promote colorectal carcinogenesis.
289
  
Strengths of the current study include accounting for changes in the inflammatory 
potential of diet over time in a large, well-characterized population of more than 110,000 
women, a long follow-up period, the inclusion of women of diverse race/ethnic groups, 
and the central adjudication of colorectal cancer diagnosis. The use of a novel dietary 
index to score diet quality based on inflammatory potential supports the evidence linking 
inflammation and colorectal cancer. Limitations include known measurement error in 
using an FFQ for the assessment of diet and its inflammatory potential over time, 
potential residual or unmeasured confounding, though we adjusted for many potential 
confounders in the models. We assumed that the random 30% of DMT participants 
sampled from year 2 until study end was representative of the entire DMT study 
population, a plausible assumption since these random subsamples were used for 
intervention monitoring in the DMT, though the sample size reduced in the last two years 
of follow-up. 
5.6 Conclusion 
A history of long-term pro-inflammatory diets increases the risk of colon cancer, 
while shorter-term stable pro-inflammatory diets increase the risk of rectal cancer. Our 
findings suggest lowering the inflammatory potential of diet as a means for colon cancer, 





















Figure 5.1. Participant flow in the administration of food frequency questionnaires in the Women’s Health Initiative (WHI) 
Observational Study (OS) and Dietary Modification Trial (DMT), 1993-2010 
















48,835 participants in the DMT 
45,954 included in final analyses (after excluding 11 due to implausible 
total energy values, 9 missing FFQs, 16 due to colorectal cancer at 
baseline, 546 missing colorectal cancer status at baseline, 701 due to 
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75,321 included in final analyses (after 
excluding  1,785 due to implausible total 
energy values, 23 missing FFQs, 838 due 
to colorectal cancer at baseline, 872 
missing colorectal cancer status at 
baseline, 1,313 due to extreme BMI 
values, and 13,524 due to single FFQ) 



















Q1 (-6.586, < -
3.184) 
(Healthiest) 
Q2 (-3.184, < -
2.103) 







Age groups (years) 
     
<50-59 6980 (30.8) 6779 (30.3) 7191 (32.5) 7596 (34.7) 8040 (37.2) 
60-69 10739 (47.4) 10527 (47.1) 10177 (46.0) 9784 (44.7) 9532 (44.1) 
70-79 4934 (21.8) 5064 (22.6) 4777 (21.5) 4502 (20.6) 4043 (18.7) 
Race/ethnicity 
     
Asian or Pacific Islander 988 (4.4) 537 (2.4) 569 (2.6) 517 (2.3) 394 (1.8) 
African American 713 (3.1) 1021 (4.6) 1428 (6.4) 1906 (8.7) 3104 (14.4) 
Hispanic/Latino 319 (1.4) 433 (1.9) 643 (2.9) 827 (3.8) 1166 (5.4) 
European American  20339 (89.8) 20092 (89.8) 19189 (86.7) 18287 (83.6) 16596 (76.8) 
Other 294 (1.3) 287 (1.3) 316 (1.4) 345 (1.6) 355 (1.6) 
Educational level 
     
< High school 87 (0.4) 146 (0.6) 194 (0.9) 252 (1.1) 413 (1.9) 
Some high school/GED 4315  (19.1) 5810 (26.0) 6407 (28.9) 7024 (32.1) 8339 (35.6) 
Some years of 
college/graduate 
18251 (80.6) 16414 (73.4) 15544 (70.2) 14606 (66.8) 12863 (59.5) 
Smoking status 
     
Never 11335 (50.0) 11625 (52.0) 11554 (52.2) 11383 (52.0) 12248 (50.9) 
Former 10572 (46.7) 9698 (43.3) 9365 (42.3) 9073 (41.5) 9276 (38.6) 
Current 746 (3.3) 1047 (4.7) 1226 (5.5) 1426 (6.5) 2247 (9.3) 
Body mass index (kg/m
2
) 







Normal weight ( <25) 9722 (42.9) 8285 (37.0) 7631 (34.5) 7009 (32.0) 6202 (28.7) 
Overweight (25.0 - <30) 7728 (34.1) 7858 (35.1) 7864 (35.5) 7750 (35.4) 7397 (34.2) 
Obese (≥30) 5203 (23.0) 6227 (27.9) 6650 (30.0) 7123 (32.6) 8016 (37.1) 
Physical activity (PA), minutes/week 
    
Not meeting PA 
recommendations 
8016 (42.2) 11810 (52.8) 12667 (57.2) 13521 (61.8) 15096 (69.8) 
Meeting PA recommendations 13090 (5.8) 10560 (47.2) 9478 (42.8) 8361 (38.2) 6519 (30.2) 
Diabetes 
     
No 20000 (88.3) 19499 (87.2) 18915 (85.4) 18482 (84.5) 17870 (82.7) 
Yes 2653 (11.7) 2871 (12.8) 3230 (14.6) 3400 (15.5) 3745 (17.2) 
Hypertension 
     
No 15986 (70.6) 15238 (68.1) 14777 (66.7) 1445 (66.0) 13799 (63.8) 
Yes 76667 (29.4) 7132 (31.9) 7368 (33.3) 7432 (34.0) 7816 (36.2) 
Arthritis 
     
No 11669 (51.5) 11425 (51.1) 11628 (52.5) 11661 (53.3) 11950 (55.3) 
Yes 10984 (48.5) 10945 (48.9) 10517 (47.5) 10221 (46.7) 9665 (44.7) 
NSAIDs use 
     
No 9504 (42.0) 9064 (40.5) 9387 (42.4) 9881 (45.2) 10479 (48.5) 
Yes 13149 (58.0) 13306 (59.5) 12758 (57.6) 12001 (54.8) 11136 (51.5) 
Duration of estrogen use by category 
    
None 14000 (61.8) 13559 (60.6) 13684 (61.8) 13729 (62.7) 14198 (65.7) 
<5 Years 2788 (12.3) 2823 (12.6) 2855 (12.9) 2900 (13.3) 2808 (13.0) 
5 to <10 Years 1789 (7.9) 1773 (7.9) 1752 (7.9) 1578 (7.2) 1470 (6.8) 
10 to <15 Years 1503 (6.6) 1464 (6.6) 1353 (6.1) 1279 (5.8) 1129 (5.2) 
15+ Years 2573 (11.4) 2751 (12.3) 2501 (11.3) 2396 (11.0) 2010 (9.3) 
Duration of estrogen & progesterone use by category 
   







<5 Years 3672 (16.2) 3316 (14.8) 3174 (14.3) 3033 (13.9) 2661 (12.3) 
5 to <10 Years 2293 (10.1) 2008 (9.0) 1823 (8.2) 1618 (7.4) 1365 (6.3) 
10 to <15 Years 1357 (6.0) 1226 (5.5) 1003 (4.5) 914 (4.2) 670 (3.1) 







Table 5.2. Risk of colorectal cancer by quintiles of cumulative average dietary inflammatory index over a ten-year period of time; 





Quintile 2 Quintile 3 Quintile 4 
Quintile 5 (Least 
healthy) 
  
Years of diet data 
assessment 
Referent OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) Ptrend 
Baseline, year 1, DMT     
n(cases/non cases) 108/7549 104/7436 89/7287 117/7251 119/7116 
 
Age adjusted 1.00 1.06 (0.82, 1.36) 0.87 (0.67, 1.14) 1.25 (0.98, 1.60) 1.30 (1.02, 1.66)* 0.008 
Multivariable-
adjusted 
1.00 0.97 (0.74, 1.27) 0.85 (0.64, 1.13) 1.11 (0.85, 1.46) 1.16 (0.88, 1.53) 0.13 
Baseline, years 1,2, DMT 
    
n(cases/non cases) 100/7734 98/7614 83/7509 101/7414 119/7304 
 
Age adjusted 1.00 1.03 (0.79, 1.34) 0.85 (0.65, 1.12) 1.15 (0.86, 1.48) 1.39 (1.08, 1.79)* 0.003 
Multivariable-
adjusted 
1.00 0.99 (0.75, 1.31) 0.85 (0.63, 1.13) 1.05 (0.79, 1.39) 1.27 (0.95, 1.68) 0.05 
Baseline, years 1-3, OS & DMT 
    
n(cases/non cases) 226/22427 257/22113 243/21902 223/21659 291/21324 
 





1.00 1.13 (0.94, 1.35) 1.08 (0.90, 1.30) 1.00 (0.83, 1.21) 1.33 (1.10, 1.61)* 0.02 
Baseline, years 1-3: OS 
    
n(cases/non cases) 137/14424 163/14370 159/14322 132/14247 187/14120 
 
Age adjusted 1.00 1.20 (0.96, 1.49) 1.18 (0.95, 1.48) 1.02 (0.81, 1.29) 1.50 (1.21, 1.86)* 0.003 








Baseline, years 1-3: DMT 
    
n(cases/non cases) 90/7808 93/7704 77/7576 96/7484 106/7370 
 
Age adjusted 1.00 1.05 (0.80, 1.38) 0.87 (0.66, 1.18) 1.20 (0.92, 1.57) 1.37 (1.06, 1.79)* 0.005 
Multivariable-
adjusted 
1.00 1.05 (0.79, 1.41) 0.88 (0.65, 1.20) 1.12 (0.84, 1.51) 1.28 (0.95, 1.73) 0.07 
Baseline, years 1-4, DMT 
    
n(cases/non cases) 77/7910 83/7832 82/7695 90/7537 86/7489 
 
Age adjusted 1.00 1.09 (0.81, 1.46) 1.07 (0.80, 1.44) 1.30 (0.98, 1.72) 1.28 (0.96, 1.70) 0.04 
Multivariable-
adjusted 
1.00 1.09 (0.80, 1.49) 1.09 (0.79, 1.49) 1.24 (0.91, 1.70) 1.22 (0.88, 1.70) 0.16 
Baseline, years 1-5, DMT 
    
n(cases/non cases) 70/8001 77/7943 71/7794 76/7638 75/7558 
 
Age adjusted 1.00 1.13 (0.83, 1.53) 1.07 (0.79, 1.46) 1.17 (0.86, 1.59) 1.25 (0.93, 1.70) 0.15 
Multivariable-
adjusted 
1.00 1.11 (0.80, 1.54) 1.04 (0.75, 1.46) 1.15 (0.83, 1.51) 1.20 (0.85, 1.71) 0.31 
Baseline, years 1-6, DMT 
    
n(cases/non cases) 61/8091 65/8006 73/7866 64/7711 67/7626 
 
Age adjusted 1.00 1.08 (0.78, 1.50) 1.16 (0.84, 1.59) 1.05 (0.75, 1.45) 1.26 (0.92, 1.74) 0.22 
Multivariable-
adjusted 
1.00 1.08 (0.76, 1.53) 1.23 (0.87, 1.74) 1.11 (0.77, 1.60) 1.24 (0.85, 1.80) 0.30 
Baseline, years 1-7, DMT 
    
n(cases/non cases) 46/8105 61/8004 57/7912 55/7728 56/7662 
 
Age adjusted 1.00 1.36 (0.93, 1.93) 1.25 (0.87, 1.79) 1.20 (0.83, 1.73) 1.39 (0.97, 2.00) 0.21 
Multivariable-
adjusted 
1.00 1.33 (0.90, 1.95) 1.24 (0.83, 1.84) 1.24 (0.83, 1.86) 1.30 (0.85, 1.98) 0.32 
Baseline, years 1-8, DMT 
    








Age adjusted 1.00 1.32 (0.90, 1.92) 1.17 (0.79, 1.73) 1.09 (0.73, 1.62) 1.26 (0.85, 1.87) 0.56 
Multivariable-
adjusted 
1.00 1.28 (0.85, 1.92) 1.14 (0.75, 1.74) 1.11 (0.72, 1.73) 1.15 (0.72, 1.82) 0.85 
Baseline, years 1-9, DMT 
    
n(cases/non cases) 30/8111 47/8010 36/7906 36/7741 37/7710 
 
Age adjusted 1.00 1.57 (1.02, 2.42)* 1.23 (0.78, 1.93) 1.28 (0.82, 2.02) 1.53 (0.98, 2.38) 0.23 
Multivariable-
adjusted 
1.00 1.57 (0.99, 2.50) 1.21 (0.74, 1.99) 1.25 (0.76, 2.07) 1.35 (0.80, 2.28) 0.64 
Baseline, years 1-10, DMT 
    
n(cases/non cases) 19/8118 37/8005 27/7877 25/7762 27/7716 
 
Age adjusted 1.00 1.83 (1.10, 3.05)* 1.44 (0.84, 2.45) 1.33 (0.78, 2.30) 1.59 (0.94, 2.72) 0.41 
Multivariable-
adjusted 
1.00 1.91 (1.09, 3.34)* 1.39 (0.77, 2.53) 1.31 (0.71, 2.41) 1.45 (0.77, 2.74) 0.84 
*Statistically significant; 
a
Hazard ratios and 95% confidence interval; 
b
All multivariable models were adjusted for age, race/ethnicity, educational level, 
smoking status, diabetes, hypertension, arthritis, NSAID use, category and duration of estrogen use, category and duration of estrogen & progesterone 





Figure 5.2. Multivariable-adjusted hazard ratios for the association between cumulative 
average DII (highest vs. lowest quintile) and colon cancer risk; Women's Health Initiative 




Figure 5.3. Multivariable-adjusted hazard ratios for the association between cumulative 
average DII (highest vs. lowest quintile) and rectal cancer risk; Women's Health Initiative 


































































Table 5.3. Risk of colorectal cancer across patterns of change in the dietary inflammatory index (DII) between baseline and year 3; 
Women's Health Initiative, 1993-2010 
 

















All participants Referent HR (95%CI)
a
 HR (95%CI) HR (95%CI) HR (95%CI) 
Colorectal cancer, 
n(cases/non cases) 
290/23169 131/9168 251/18575 122/9476 277/18025 
Age adjusted 1.00 1.22 (1.00, 1.49) 1.12 (0.95, 1.32) 1.12 (0.92, 1.38) 1.29 (1.10, 1.52) 
Multivariable-adjusted
b
 1.00 1.13 (0.92, 1.39) 1.04 (0.88, 1.24) 1.04 (0.84, 1.29) 1.18 (0.99, 1.41)* 
Risk by colorectal cancer 
subsite      
Colon cancer n(cases/non 
cases) 
249/23210 107/9192 215/18611 103/9495 226/18076 
Age adjusted 1.00 1.15 (0.92, 1.45) 1.10 (0.92, 1.32) 1.09 (0.86, 1.37) 1.27 (1.06, 1.52) 
Multivariable-adjusted 1.00 1.06 (0.86, 1.36) 1.04 (0.86, 1.25) 1.01 (0.80, 1.28) 1.11 (0.91, 1.35) 
Proximal
c
 colon  n(cases/non 
cases) 
142/23209 63/9192 131/18611 69/9495 142/18076 
Age adjusted 1.00 1.19 (0.87, 1.61) 1.18 (0.93, 1.49) 1.28 (0.96, 1.70) 1.40 (1.11, 1.77) 
Multivariable-adjusted 1.00 1.12 (0.83, 1.51) 1.11 (0.87, 1.42) 1.20 (0.90, 1.62) 1.23 (0.96, 1.59) 
Distal
c
 colon  n(cases/non 
cases) 
60/23210 22/9191 55/18611 22/9495 48/18075 
Age adjusted 1.00 0.98 (0.60, 1.59) 1.16 (0.80, 1.67) 0.95 (0.58, 1.54) 1.10 (0.75, 1.61) 
Multivariable-adjusted 1.00 0.93 (0.65, 1.52) 1.10 (0.76, 1.60) 0.89 (0.54, 1.47) 0.99 (0.66, 1.49) 
Rectal
d








Age adjusted 1.00 1.37 (0.84, 2.25) 1.19 (0.79, 1.80) 1.13 (0.67, 1.90) 1.70 (1.15, 2.51) 
Multivariable-adjusted 1.00 1.24 (0.75, 2.04) 1.12 (0.73, 1.72) 1.10 (0.64, 1.88) 1.53 (1.01, 2.32)* 
*Statistically significant in multivariable models; 
a
Hazard ratio and 95% confidence interval; 
b
All multivariable models were adjusted for age, 
race/ethnicity, educational level, smoking status, diabetes, hypertension, arthritis, NSAID use, category and duration of estrogen use, category and 
duration of estrogen & progesterone use, dietary modification trial arm , body mass index, physical activity; 
c
ICD-O-2 codes used to define location 
of colon cancer include C18.0 (cecum), C18.2 (ascending colon, right colon), C18.3 (hepatic flexure of colon), C18.4 (transverse colon), C18.5 
(splenic flexure of colon), C18.6 (descending colon, left colon) and  C18.7 (sigmoid colon); 
d
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Introduction: We utilized the dietary inflammatory index (DII) to evaluate 
associations between cumulative history, and changes over time in dietary inflammatory 
potential, and risk of breast cancer in the Women’s Health Initiative (WHI). Methods: 
We included 106,644 postmenopausal women aged 50-79 years recruited from 1993-
1998 into the WHI Observational Study and Dietary Modification Trial, and followed 
through September 30, 2010. We utilized data from food frequency questionnaires 
(FFQs) to calculate ten cumulative averages of DII, incrementally from baseline to Year 
10, categorized each average into quintiles, and used to estimate hazards ratios (HR) and 
95% confidence intervals (95% CI) for invasive breast cancer incidence in multiple Cox 
proportional hazards regression models. We also derived patterns of changes in DII in a 
subset of 76,329 women between baseline and Year 3, and used multiple Cox regression 
models to estimate hazard ratios (HR) and 95% CI for incidence of invasive breast cancer 
and its subtypes.  Results: During an average 11.7 years, 4,242 cases of invasive breast 
cancer were identified. There was no substantial association between any of the ten 
averages of cumulative DII calculated between baseline and Year 10, and risk of invasive 
breast cancer. Also, HR revealed no substantial association between changes in DII 
between baseline and Year 3, and risk of invasive breast cancer or any of its subtypes. 
Conclusion: We did not observe a significant association between a history of long-term 
pro-inflammatory diets as well as shorter-term changes in the inflammatory potential of 
diets, and breast cancer risk in postmenopausal women. Findings imply that lowering the 
inflammatory potential of diet may not be a major means for breast cancer prevention. 
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Women’s Health Initiative 
6.2 Introduction 
Breast cancer is the most commonly diagnosed cancer in American women
173
 and 
most of the risk factors, including reproductive factors,
290
 and family history of breast 
cancer,
291
 are generally non-modifiable. Diet, a potentially modifiable factor has been 





 shown to be associated with increased risk. The fact that people 
eat meals consisting of a wide variety of individual foods with potentially complex 
interactions among the foods and nutrients has led to a growing interest in the 
examination of broader dietary patterns in relation to breast cancer risk.   
Results of previous studies examining the association between dietary patterns 
and breast cancer risk are inconsistent.
41-47,181,182,208-211
 Some studies have found an 
increased risk of breast cancer with the Western (or unhealthy) diet pattern
41,42
 or a 
reduced risk with the prudent (or healthy) pattern,
181,182
 while others failed to observe a 
significant association.
43-45
 Indeed, some studies have found results contrary to 
hypothesized associations; that is, higher consumption of the prudent pattern  associated 
with increased risk
42
 and higher consumption of the Western pattern  associated with 
reduced risk
208
 of breast cancer. Additionally, findings from three large cohort studies did 




Given the central role of chronic inflammation in the carcinogenesis 
process
110,292,293
 dietary patterns that modulate inflammation may be more predictive of 
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breast cancer risk. Additionally, dietary behaviors mainly influence chronic disease 
outcomes, including breast cancer, when they persist for a longer period of time,
31
 
therefore changes in diet over time or the cumulative history of diet over time may be 
more predictive of breast cancer risk, compared to diet assessed at one point in time. We 
have shown that the inflammatory potential of diet decreased significantly over time 
among women enrolled in the Women’s Health Initiative Dietary Modification Trial 
(WHI DMT) (Tabung FK, Steck SE, Zhang J, Ma Y, Liese AD, Tylavsky FA, et al., 
unpublished data, 2014). In the current study, we utilized the dietary inflammatory index 
(DII)
38,39
  to investigate the role of cumulative history, as well as changes in the 
inflammatory potential of diet, on breast cancer risk in postmenopausal women. 
6.3 Methods 
6.3.1 Study population 
The WHI study is a large and complex clinical investigation of strategies for the 
prevention and control of some of the most common causes of morbidity and mortality 
among postmenopausal women. The design of the WHI has been described in detail 
elsewhere.
40
 Briefly, The WHI began in 1992, implemented in 40 sites across the United 
States, and enrolled a total of 161,808 women between 1993 and 1998. The WHI enrolled 
93,676 women into an Observational Study (OS) and 68,132 participants into Clinical 
Trials (CT), and followed them until September 30, 2010.
265
 The CTs included three 
components: Hormone Therapy, calcium and vitamin D, and the DMT. For the DMT, 
women were randomly assigned to a usual-diet comparison group (n=29,294) or an 
intervention group (n=19,541) with a 20% low-fat dietary pattern with increased 
vegetables, fruits, and whole grains. Women who proved to be ineligible for, or who were 
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unwilling to enroll in the CT components were invited to be part of the prospective 
cohort of women in the OS.
40
  
Exclusion criteria for both the OS and CT included any medical condition 
associated with a predicted survival of less than three years, alcoholism, other drug 
dependency, mental illness (e.g., major depressive disorder), dementia, active 
participation in another intervention trial and not likely to live in the area for at least 3 
years. Demographic information and dietary data were obtained by self-report using 
standardized questionnaires. Certified staff performed physical measurements, including 
blood pressure, height and weight, and blood samples at the baseline clinic visit. Women 
were further excluded from the DMT if their diets were assessed to have <32% energy 
from fat.
266
 The WHI protocol was approved by the institutional review boards at the 
Clinical Coordinating Center (CCC) at the Fred Hutchinson Cancer Research Center 
(Seattle, WA) and at each of the 40 Clinical Centers.
14
  
6.3.2 Diet assessment 
Figure 6.1 describes the administration of food frequency questionnaires (FFQ) in 
the WHI. During screening for the WHI, all participants completed a baseline FFQ. At 
follow-up, the FFQ was completed at Year 3 for ~90% of OS participants. About 92% of 
DMT participants completed an FFQ in Year 1, and a random third of participants were 
invited to complete an FFQ annually from Year 2 until study end (approximately ten 
years later) (Figure 6.1). There was an average of two FFQs per participant in the OS and 
three FFQs per participant in the DMT. The 122-item WHI FFQ line item nutrient data 
was obtained from the University of Minnesota’s Nutrient Data system for research 
(NDSR) version 4.03_31 software,
272
 which is based on the US Department of 
 
116 
Agriculture Standard Reference Releases and manufacturer information. The WHI FFQ 
has shown comparable results with 24-hour dietary recall interviews and food records.
266
 
6.3.3 The dietary inflammatory index (DII) 
Details of the development
38
 and construct validation
39
 of the DII have been 
described elsewhere. Briefly, an extensive literature search was performed to obtain peer-
reviewed journal articles that examined the association between six well known 
inflammatory biomarkers (Interleukin (IL)-1β, IL-4, IL-6, IL-10, tumor necrosis factor 
alpha, and C-reactive protein) and 45 specific foods and nutrients (components of the 
DII).  Scores were derived and standardized to a representative global diet database 
constructed based on 11 datasets from diverse populations in different parts of the world.  
Overall DII scores for each individual participant represent the sum of each of the DII 
components in relation to the comparison global diet database.
38
 The DII score 
characterizes an individual’s diet on a continuum from maximally anti-inflammatory to 
maximally pro-inflammatory, with a higher DII score indicating a more pro-
inflammatory diet and a lower (i.e., more negative) DII score indicating a more anti-
inflammatory diet.  In the WHI FFQ, 32 of the 45 original DII components were 
available for inclusion in the overall DII score (see
38
 for list of 45 DII components). 
Components such as ginger, turmeric, garlic, oregano, pepper, rosemary, eugenol, 
saffron, flavan-3-ol, flavones, flavonols, flavonones, anthocyanidins that are included in 
the original DII calculation
38
 were not included in the current study because they were 
not  available from the WHI FFQ.  
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6.3.4 Outcomes assessment 
The WHI outcomes ascertainment and adjudication process has been previously 
described.
267
 Briefly, participants (or next-of-kin) self-reported cancer diagnoses reported 
on questionnaires annually in the OS or semiannually in the CT through 2005 and 
annually in all thereafter. Invasive breast cancer was documented and coded according to 
primary site, diagnosis date, extent of disease (stage, tumor size, and laterality), tumor 
morphology (behavior, grade, histology) her2neu status and estrogen and progesterone 
receptors (ER, PR) status. Incident invasive breast cancer, including second primaries, 
were ascertained and adjudicated, but recurrent cancers were not included. For the full 
coding of the cancer, pathology reports from diagnostic aspirations, biopsies, and 
surgeries, plus the discharge summary, were used.  
Breast cancer outcomes for the current study included invasive breast cancer, and 
molecular and histologic subtypes of breast cancer. Molecular subtypes were defined 
based on previous work by Carey et al., as follows: triple negative (HER2−, ER−, PR−), 
(HER2+, ER−, PR−) subtype, luminal A (ER+ and/or PR+, HER2−), and luminal B 
(ER+ and/or PR+, HER2+).
294
 The histological subtypes were defined based on SEER 
morphology codes. These included ductal carcinoma (including intraductal carcinoma, 
8500/2, and infiltrating ductal carcinoma, 8500/3), lobular carcinoma (including lobular 
carcinoma, 8520/3, and lobular carcinoma in situ, 8520/2), and a combination of ductal 
and lobular carcinomas (8522/3 and 8520/2). Survival time was defined as days from 
enrollment or randomization until breast cancer diagnosis while censoring time was 
defined as days from enrollment or randomization until death or last contact occurring on 
or before September 30, 2010, in participants without breast cancer. 
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6.3.5 Statistical analysis 
We utilized data from 142,511 women participating in the WHI OS (93,676) and 
DMT (48,835). Exclusion criteria included women with a history of breast cancer at 
baseline or missing breast cancer status at baseline (n=5,078), those who reported breast 
removal at baseline (n=277), or those with single FFQs or missing FFQs (n=14,655), as 
well as women with implausible reported total energy intake values (≤600 kcal/day or 
≥5000 kcal/day) (n=1,796) or extreme BMI values (<15kg/m
2
 or > 50kg/m
2
) (n=1,991) 
(Figure 6.1). Additionally, participants with missing data in the covariates listed below 
(n=10,797) were excluded, leaving a total of 106,644 participants for these analyses 
(68,319 in OS and 38,325 in DMT). Frequencies and percentages were computed to 
describe the distribution of covariates across quintiles of cumulative average DII for the 
DII assessed from baseline to Year 3. 
To determine how cumulative history of the inflammatory potential of diet, 
affects breast cancer risk over time, we calculated cumulative averages of DII 
incrementally starting from the average between baseline and year one DII 
172
. 
The cumulative average was then categorized into quintiles, and used in multiple  Cox 
proportional hazards (PH) models to estimate hazard ratios (HR) for the incidence of 
invasive breast cancer, while excluding breast cancer cases diagnosed prior to year one. 
This approach was repeated for the average DII of baseline, year one, and year two with 
breast cancer cases diagnosed prior to year two excluded to avoid the possibility of 
change in diet due to subclinical disease and to include only participants at risk of 
developing breast cancer going forward. This approach was repeated until DII estimates 





To determine how changes in patterns of the inflammatory potential of diet over 
time affect breast cancer risk, we calculated the DII from baseline and year 3 FFQs 
administered to 76,329 women in the OS and DMT. We categorized the DII at both time 
points into quintiles (Q) and further categorized changes in the inflammatory potential of 
diet based on quintile differences between baseline and year 3, as follows:  
6. Anti-inflammatory stable: Q1 or Q2 at both time points or change from Q3 to Q2;  
7. Anti-inflammatory change: changes ≤ -2Q;  
8. Neutral inflammation stable: changes from Q2 to Q3, Q4 to Q3 or stable at Q3 at 
both time points;  
9. Pro-inflammatory change: changes ≥ 2Q;  
10. Pro-inflammatory stable: Q4 or Q5 at both time points, or change from Q3 to Q4.  
The names given to these categories of DII changes were meant to be qualitative. 
Next, Cox regression PH models were used to estimate hazard ratios (HR) and 95% CI 
for the incidence of invasive breast cancer including the molecular and histological 
subtypes, by patterns of DII changes and with adjustment for multiple covariates. The 
anti-inflammatory stable category, considered to be the healthiest category, was the 
referent for all models. 
All multivariable-adjusted models included the following covariates as potential 
confounders based on ≥10% change in HR between age-adjusted models with and 
without the potential confounder: age group (years) (50-59, 60-69, 70-79), race/ethnicity 
(European American (EA), African American (AA), Hispanic (HP), Asian or Pacific 
Islander (A/PI) and Other); educational levels (less than high school, some high school 
/GED, at least some college/graduate education), smoking status (current, past, and 
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never), body mass index [BMI= weight(kg)/height(m)
2





), and obese (≥30kg/m
2
)); physical activity (PA),categorized 
based on public health recommendations,
284
 as meeting or not meeting PA 
recommendations (≥150 minutes/week of moderate intensity PA or ≥75 minutes/week of 
vigorous intensity PA versus<150 minutes/week of moderate intensity PA or <75 
minutes/week of vigorous intensity PA, respectively); use of non-steroidal anti-
inflammatory drug (NSAID) (yes/no); category and duration of estrogen use and category 
and duration of combined estrogen and progesterone use both categorized into five 
groups (none, <5y, 5 to <10y, 10 to <15y, and ≥15y), total energy intake (Kcal/day). 
Some covariates did not change HR of the association between age-adjusted DII and 
breast cancer risk by ≥10% and were therefore not included in the final models. These 
included study participation (OS/DMT), age at menarche, age at first birth, number of 
live births, total duration of breastfeeding, mammography in the 2 years preceding study 
enrollment, oophorectomy status, and first degree relative with breast cancer. Data on 
potential confounders were collected by self-administered questionnaires on 
demographics, medical history, and lifestyle factors.
40
  
Each covariate in the final models of both the cumulative average DII and 
patterns of DII change was tested for proportional hazards using cumulative sums of 
Martingale-based residuals. Age group and combined use of estrogen and progesterone 
violated the PH assumption and all models were therefore stratified by these two 
covariates. To determine whether the association between both the cumulative average 
DII and changes in the DII and breast cancer incidence differed by age, race/ethnicity, 
education, BMI and combined use of estrogen and progesterone, we included interaction 
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terms for these covariates in the models and assessed significant effect modification at p 
<0.05. None of the interaction terms was significant. We evaluated 95% CIs to determine 
statistical significance. Statistical analyses were conducted using SAS version 9.3 (SAS 
Institute, Cary, NC), and all tests were two-sided. 
6.4 Results 
Table 6.1 presents the distribution of participants’ characteristics across quintiles 
of the cumulative average DII between baseline and Year 3. Participants with higher 
cumulative average DII scores (representing a more pro-inflammatory diet) consisted of a 
higher proportion of women who were AA or HP, overweight or obese, current smokers, 
not meeting physical activity guidelines, and with lower educational attainment. In 
contrast, participants with a more anti-inflammatory diet consisted of a higher proportion 
of women who were EA or A/PI, had a normal BMI, were highly educated, and adhered 
to physical activity guidelines. Participants were followed for an average 11.7 years, 
during which 4,242 cases of invasive breast cancer were identified. 
Table 6.2 presents HR of the association between cumulative average DII and risk 
of invasive breast cancer. There was an inverse association between cumulative DII and 
invasive breast cancer comparing quintiles 2 and 1 in the first year of follow-up (HR, 
0.81; 95%CI, 0.70, 0.93; Ptrend, 0.14), and in the second year of follow-up (HR, 0.84; 
95%CI, 0.73, 0.98; Ptrend, 0.35), but the trends across quintiles of cumulative average DII 
were not significant for these inverse associations. No other statistically significant 
associations between averages of cumulative DII and risk of invasive breast cancer were 
observed in the multiple adjusted models.  
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Table 6.3 shows HR for the association between changes in DII between baseline 
and Year 3, and risk of invasive breast cancer and its subtypes. Overall, there was no 
substantial association between changes in DII over time and total breast cancer or any of 
its subtypes. However, there was an inverse association between changes in DII and risk 
of triple negative breast cancer (HR, 0.47; 95%CI, 0.28, 0.79), comparing participants in 
the anti-inflammatory change category to those in the anti-inflammatory stable category 
of changes in DII between baseline and Year 3. In participants with (HER2+, ER−, PR−) 
subtype of breast cancer, HRs were indicative of a positive association, comparing 
participants in the pro-inflammatory stable category to those in the anti-inflammatory 
stable category of changes in DII, but did not attain statistical significance (HR, 1.60; 
95%CI, 0.91, 2.80) (Table 6.3). 
6.5 Discussion 
In this large prospective study of the role of cumulative history, and changes in 
the inflammatory potential of diet over time in breast cancer risk, we observed no 
significant association between either 1) the cumulative history of dietary inflammatory 
potential, or 2) changes in dietary inflammatory potential over time, and risk of invasive 
breast cancer or subtypes of breast cancer in postmenopausal women, with the exception 
of a reduced risk of triple negative breast cancer among women who moved toward a 
more anti-inflammatory diet compared to those who consumed a more stable anti-
inflammatory diet from baseline to Year 3. To the best of our knowledge, this is the first 
study to characterize the association between the cumulative history, or changes over 
time in the inflammatory potential of diet, and risk of breast cancer. Given that FFQs 
were administered to OS participants at baseline and Year 3 only; a cumulative average 
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DII could be calculated for OS participants at Year 3 only and analyses at all other time 
points included DMT participants. We selected these two time points for the analyses of 
changes in the DII over time, to include the maximum number of participants with FFQs 
(Figure 6.1).   
Our results are generally similar to many previous prospective studies that did not 
observe significant associations between dietary patterns and breast cancer risk,
44,46,47
 
though these other studies assessed diet quality at only one point in time. Other previous 
studies have described heterogeneity of the association between dietary patterns and 
breast cancer by hormone receptor status.
44,295,296
 Cottet et al. found evidence of an 
increased risk of ER+/PR+ tumors with a Western dietary pattern and reduced risk of 
ER+/PR− tumors with a Mediterranean pattern in a French Cohort study.
295
 Fung et al 
found that higher consumptions of fruits and vegetables was significantly associated with 
decreased risk for ER- breast cancer in the Nurses Health Study,
44
 while Gaudet et al., 
found an inverse association between high fruit and vegetable intake and breast cancer 
risk among postmenopausal women with ER+ tumors.
296
 We cannot rule out that chance 
may account for our finding of an inverse association for invasive breast cancer 
comparing quintile 2 with quintile 1 of cumulative average DII in the first two years of 
follow-up in the DMT; and an inverse association in participants with triple negative 
tumors; given the number of comparisons made in this study. 





 Generally, dietary patterns have been 
shown to modulate inflammation,
48-50
 and inflammation exerts an important role in the 
carcinogenesis process.
10,300
 However, our findings imply that inflammation may not be a 
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primary mechanism through which diet substantially influences breast cancer risk. 
Obesity, a state of low-grade chronic inflammation
229,230
 and a risk factor for breast 
cancer in postmenopausal women,
301
 has been suggested to increase breast cancer risk 
mainly through the hormonal pathway, with increased exposure to endogenous estrogen 
from adipose tissue.
302,303
 Indeed, though concentrations of inflammatory markers have 
been found to be higher in obese than normal weight women,
304
 a meta-analysis of 
prospective studies did not find an association between inflammatory biomarkers and 
breast cancer risk,
305
 further indicating that inflammation may not play an important role 
in breast cancer development. Also, there was no data on inflammatory breast cancer in 
the WHI, for an assessment of the association of the inflammatory potential of diet and 
risk of this subtype of breast cancer. 
While most of the evidence is consistent that chronic inflammation increases the 
risk of breast cancer recurrence or survival,
94-96
 the evidence has been inconsistent for the 
association between biomarkers of inflammation and breast cancer incidence. Studies of 
the association between regular use of aspirin and other NSAIDS and risk of breast 
cancer in postmenopausal women have found inconsistent results.
300,306
 However, two 
meta-analyses showed that regular use of aspirin and other NSAIDs is associated with 
reduced risk of breast cancer,
307,308
 though these findings were not supported by results 
from randomized controlled trials.
206,309
 
In contrast, hyperinsulinemia may play a more important role in breast 
carcinogenesis. Hyperinsulinemia largely explained the association between obesity and 
postmenopausal breast cancer in a case-cohort study,
299
 while glucose and insulin-like 
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growth factors have been found to be positively associated with breast cancer 
development in postmenopausal women.
310
 
Strengths of the current study include accounting for changes in the inflammatory 
potential of diet over time in a large, well-characterized population of more than 106,000 
women, a long follow-up period, the inclusion of women of diverse race/ethnic groups, 
and the central adjudication of breast cancer diagnosis. The use of a novel dietary index 
to score diet quality based on inflammatory potential at multiple time points provides 
evidence that inflammation may not be substantially linked to breast cancer risk. 
Limitations include known measurement error in using an FFQ for the assessment of diet 
and its inflammatory potential over time, and potential residual or unmeasured 
confounding though we adjusted for many potential confounders in the models. We 
assumed that the random 30% of DMT participants sampled from year 2 until study end 
was representative of the entire DMT study population, a plausible assumption since 
these random subsamples were used for intervention monitoring in the DMT, though the 
sample size reduced substantially in the last two years of follow-up. 
6.6 Conclusion 
In this large prospective study, we did not observe a significant association 
between a history of long-term pro-inflammatory diets as well as shorter-term changes in 
the inflammatory potential of diets, and breast cancer risk in postmenopausal women. 
Our findings imply that lowering the inflammatory potential of diet may not be a major 
means for breast cancer prevention and that if there is a role for diet in breast cancer 


















Figure 6.1. Participant flow in the administration of food frequency questionnaires in the Women’s Health Initiative (WHI) 
Observational Study (OS) and Dietary Modification Trial (DMT), 1993-2010 
















48,835 participants in the DMT 
46,467 included in final analyses (after excluding 11 due to implausible 
total energy values, 9 missing FFQs, 3 due to breast cancer at baseline, 
1 missing breast cancer status at baseline, 11 due to breast removal at 
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72,247  included in final analyses (after 
excluding  1,785 due to implausible total 
energy values, 23 missing FFQs, 4,953 
due to breast cancer at baseline, 121 
missing breast cancer status at baseline, 
266 due to breast removal at baseline,  
1,280 due to extreme BMI values, and 
13,001 due to single FFQ) 
























Q3 (-2.085, < 
-0.710) 





Age groups (years) 
     
<50-59 6703 (30.8) 6541 (30.4) 6940 (32.6) 7344 (34.8) 7830 (37.4) 
60-69 10346 (47.5) 10103 (46.9) 9775 (45.9) 9437 (44.7) 9195 (43.9) 
70-79 4715 (21.7) 4890 (22.7) 4582 (21.5) 4325 (20.5) 3918 (18.7) 
Race/ethnicity 
     
Asian or Pacific Islander 964 (4.4) 518 (2.4) 551 (2.6) 512 (2.4) 378 (1.8) 
African American 718 (3.3) 1000 (4.6) 1380 (6.5) 18796 (8.9) 3052 (14.6) 
Hispanic/Latino 316 (1.5) 426 (2.0) 636 (3.0) 823 (3.9) 1152 (5.5) 
European American  19473 (89.5) 19303 (89.6) 18418 (86.5) 17556 (83.2) 16007 (76.4) 
Other 293 (1.3) 2879 (1.4) 305 (1.4) 336 (1.6) 354 (1.7) 
Educational level 
     
< High school 83 (0.4) 143 (0.7) 205 (1.0) 257 (1.2) 415 (2.0) 
Some high school/GED 4210 (19.3) 56482 (26.2) 6193 (29.1) 6829 (32.4) 8123 (38.8) 
Some years of college/graduate 17471 (80.3) 
157434 
(73.1) 
14899 (69.9) 14020 (66.4) 12405 (59.2) 
Smoking status 
     
Never 10870 (49.9) 11198 (52.0) 11102 (52.1) 10994 (52.1) 10757 (51.4) 
Former 101481 (46.6) 9308 (43.2) 9004 (42.3) 8724 (41.3) 8209 (39.2) 
Current 746 (3.4) 1028 (4.8) 1191 (5.6) 1388 (6.6) 1977 (9.4) 
Body mass index (kg/m
2
) 
     







Overweight (25.0 - <30) 7435 (34.2) 7591 (35.2) 7585 (35.6) 7471 (35.4) 7146 (34.1) 
Obese (≥30) 5093 (23.4) 6046 (28.1) 6422 (30.2) 69047 (32.7) 7785 (36.2) 
Physical activity (PA), 
minutes/week      





12221 (57.4) 130938 (62.0) 14690 (70.1) 
Meeting PA recommendations 125497 (57.7) 
100611 
(46.7) 
90769 (42.6) 8013 (38.0) 6253 (29.9) 
NSAIDs use 
     
No 9135 (42.0) 8684 (40.3) 8996 (42.2) 9506 (45.0) 10116 (48.3) 
Yes 12629 (58.0) 12850 (59.7) 12301 (57.8) 11600 (55.0) 10827 (51.7) 
Duration of estrogen use by category 
    
None 13342 (61.3) 12972 (60.2) 13067 (61.4) 13178 (62.4) 13690 (65.4) 
<5 Years 2682 (12.3) 2720 (12.6) 2768 (13.0) 2839 (13.5) 2745 (13.1) 
5 to <10 Years 1746 (8.0) 1713 (8.0) 1710 (8.0) 1523 (7.2) 1433 (6.8) 
10 to <15 Years 1480 (6.8) 1412 (6.6) 1319 (6.2) 1239 (5.9) 1102 (5.3) 
15+ Years 2514 (11.6) 2717 (12.6) 2433 (11.4) 2327 (11.0) 1973 (9.4) 
Duration of estrogen and progesterone use by category    
None 14138 (65.0) 14636 (68.0) 15036 (70.6) 15352 (72.7) 16067 (76.7) 
<5 Years 3551 (16.3) 3228 (15.0) 3047 (14.3) 2916 (13.8) 2606 (12.5) 
5 to <10 Years 2206 (10.1) 1906 (8.9) 1763 (8.3) 1567 (7.4) 1300 (6.2) 
10 to <15 Years 1308 (6.0) 1177 (5.4) 973 (4.6) 880 (4.2) 657 (3.1) 







Table 6.2. Risk of invasive breast cancer by quintiles of cumulative average dietary inflammatory index over a ten-year period of time; 





Quintile 2 Quintile 3 Quintile 4 
Quintile 5 
(Least healthy)   
  Referent HR (95%CI)
a
 HR (95%CI) HR (95%CI) HR (95%CI) Ptrend 
Baseline, year 1, DMT     




419/7257 329/7231 353/7058 399/6995 365/6928 
 





1.00 0.81 (0.70, 0.93)* 0.90 (0.78, 1.04) 1.04 (0.91, 1.20) 0.99 (0.86, 1.15) 0.14 
Baseline, years 1,2, DMT      
Breast cancer 
n(cases/non cases) 
387/7431 317/7417 335/7245 364/7165 332/7128 
 
Age adjusted 1.00 0.86 (0.75, 0.99) 0.90 (0.78, 1.03) 0.99 (0.87, 1.13) 0.96 (0.84, 1.10) 0.70 
Multivariable-
adjusted 
1.00 0.84 (0.73, 0.98)* 0.93 (0.80, 1.07) 1.03 (0.89, 1.19) 0.98 (0.84, 1.15) 0.35 
Baseline, years 1-3, OS and DMT     
Breast cancer 
n(cases/non cases) 
909/20855 885/20649 832/20465 819/20287 797/20146 
 
Age adjusted 1.00 1.00 (0.92, 1.10) 0.97 (0.88, 1.06) 0.97 (0.88, 1.06) 0.98 (0.90, 1.08) 0.55 
Multivariable-
adjusted 
1.00 1.00 (0.91, 1.10) 0.98 (0.89, 1.07) 0.99 (0.90, 1.10) 1.02 (0.92, 1.14) 0.68 
Baseline, years 1-3: OS      
Breast cancer 
n(cases/non cases) 
561/13155 578/13121 537/13142 506/13102 476/13141 
 









1.00 1.05 (0.94, 1.19) 1.00 (0.89, 1.13) 0.98 (0.86, 1.11) 0.98 (0.86, 1.12) 0.42 
Baseline, years 1-3: DMT      
Breast cancer 
n(cases/non cases) 
345/7523 305/7477 301/7321 329/7229 304/7191 
 
Age adjusted 1.00 0.93 (0.80, 1.08) 0.91 (0.78, 1.05) 1.03 (0.89, 1.18) 0.98 (0.85, 1.13) 0.67 
Multivariable-
adjusted 
1.00 0.91 (0.78, 1.07) 0.93 (0.80, 1.09) 1.05 (0.90, 1.23) 1.02 (0.86, 1.20) 0.35 
Baseline, years 1-4, DMT      
Breast cancer 
n(cases/non cases) 
311/7625 280/7575 253/7483 308/7280 267/7294 
 
Age adjusted 1.00 0.95 (0.81, 1.11) 0.87 (0.74, 1.01) 1.07 (0.93, 1.25) 0.98 (0.84, 1.14) 0.64 
Multivariable-
adjusted 
1.00 0.93 (0.79, 1.09) 0.86 (0.73, 1.02) 1.09 (0.93, 1.28) 0.98 (0.82, 1.17) 0.48 
Baseline, years 1-5, DMT      
Breast cancer 
n(cases/non cases) 
264/7732 263/7674 232/7564 246/7398 247/7356 
 
Age adjusted 1.00 1.04 (0.89, 1.23) 0.95 (0.81, 1.12) 1.01 (0.86, 1.19) 1.09 (0.93, 1.28) 0.38 
Multivariable-
adjusted 
1.00 1.03 (0.86, 1.22) 0.93 (0.78, 1.11) 1.02 (0.86, 1.22) 1.08 (0.89, 1.30) 0.44 
Baseline, years 1-6, DMT      
Breast cancer 
n(cases/non cases) 
223/7821 216/7747 207/7629 210/7467 209/7421 
 
Age adjusted 1.00 1.03 (0.86, 1.22) 1.00 (0.84, 1.19) 1.02 (0.85, 1.22) 1.11 (0.93, 1.32) 0.27 
Multivariable-
adjusted 
1.00 1.00 (0.83, 1.21) 0.97 (0.80, 1.18) 1.03 (0.84, 1.25) 1.07 (0.88, 1.22) 0.43 
Baseline, years 1-7, DMT      
Breast cancer 
n(cases/non cases) 








Age adjusted 1.00 0.99 (0.81, 1.20) 0.96 (0.79, 1.17) 1.04 (0.86, 1.26) 1.12 (0.93, 1.36) 0.16 
Multivariable-
adjusted 
1.00 1.00 (0.81, 1.23) 0.97 (0.78, 1.20) 1.09 (0.88, 1.36) 1.14 (0.91, 1.43) 0.15 
Baseline, years 1-8, DMT      
Breast cancer 
n(cases/non cases) 
149/7839 145/7756 141/7685 160/7450 137/7506 
 
Age adjusted 1.00 1.03 (0.83, 1.27) 0.98 (0.79, 1.21) 1.13 (0.92, 1.39) 1.10 (0.89, 1.36) 0.21 
Multivariable-
adjusted 
1.00 1.02 (0.81, 1.29) 1.01 (0.80, 1.27) 1.22 (0.96, 1.53) 1.11 (0.86, 1.43) 0.18 
Baseline, years 1-9, DMT      
Breast cancer 
n(cases/non cases) 
114/7836 112/7765 118/7653 121/7488 110/7519 
 
Age adjusted 1.00 0.99 (0.78, 1.26) 1.04 (0.82, 1.32) 1.10 (0.87, 1.39) 1.15 (0.97, 1.46) 0.15 
Multivariable-
adjusted 
1.00 1.03 (0.79, 1.34) 1.11 (0.85, 1.44) 1.20 (0.92, 1.56) 1.19 ( 0.89, 1.58) 0.14 
Baseline, years 1-10, DMT      
Breast cancer 
n(cases/non cases) 
78/7848 80/7761 87/7625 92/7501 82/7526 
 
Age adjusted 1.00 1.04 (0.78, 1.38) 1.13 (0.86, 1.50) 1.19 (0.91, 1.57) 1.23 (0.93, 1.62) 0.09 
Multivariable-
adjusted 
1.00 1.09 (0.80, 1.49) 1.21 (0.88, 1.65) 1.34 (0.98, 1.83) 1.32 (0.94, 1.84) 0.05* 
 *Statistically significant multivariable-adjusted HR;
 a
HR=hazard ratio, CI=confidence interval; 
b
cases/non-cases in the multivariable models; 
c
all 
models were adjusted for age, race/ethnicity, education, smoking status, physical activity, body mass index, NSAID use,  category and duration of 










Table 6.3. Risk of breast cancer by subtype, across patterns of change in the dietary inflammatory index (DII) between baseline and 
year 3; Women's Health Initiative, 1993-2010 
 
 




















 HR (95%CI) HR (95%CI) HR (95%CI) 
Invasive breast cancer  





1293/21015 456/8542 897/17163 473/8743 835/16912 





1.00 0.91 (0.81, 1.02) 0.91 (0.83, 0.99)* 0.98 (0.88, 1.10) 0.94 (0.85, 1.04) 
Molecular subtypes of 
breast cancer      
Triple negative (HER2−, 
ER−, PR−)      
Breast cancer cases/non-
cases 
90/21015 17/8542 64/17163 36/8743 67/16912 
Age adjusted model 1.00 0.52 (0.32, 0.85) 0.88 (0.64, 1.21) 1.07 (0.74, 1.55) 1.02 (0.75, 1.38) 
Multivariable adjusted 
model 
1.00 0.47 (0.28, 0.79)* 0.88 (0.63, 1.22) 1.02 (0.68, 1.52) 0.93 (0.66, 1.33) 
HER2+/ER− subtype 
(HER2+, ER−, PR−)      








Age adjusted model 1.00 1.01 (0.54, 1.87) 1.14 (0.70, 1.85) 1.24 (0.69, 2.23) 1.47 (0.93, 2.32) 
Multivariable adjusted 
model 
1.00 1.14 (0.57, 2.28) 1.38 (0.79, 2.39) 1.46 (0.79, 2.82) 1.60 (0.91, 2.80) 
luminal A (ER+ and/or 
PR+, HER2−)       
Breast cancer cases/non-
cases 
649/21015 238/8542 460/17163 257/8743 404/16912 
Age adjusted model 1.00 0.94 (0.81, 1.08) 0.91 (0.81, 1.02) 0.98 (0.85, 1.13) 0.83 (0.73, 0.93) 
Multivariable adjusted 
model 
1.00 0.94 (0.81, 1.10) 0.92 (0.81, 1.04) 1.03 (0.89, 1.19) 0.88 (0.77, 1.01) 
luminal B (ER+ and/or 
PR+, HER2+)      
Breast cancer cases/non-
cases 
106/21015 35/8542 63/17163 33/8743 70/16912 
Age adjusted model 1.00 0.80 (0.55, 1.17) 0.78 (0.58, 1.07) 0.76 (0.52, 1.11) 0.86 (0.64, 1.16) 
Multivariable adjusted 
model 
1.00 0.92 (0.62, 1.35) 0.84 (0.61, 1.15) 0.92 (0.61, 1.37) 1.11 (0.80, 1.54) 
Histologic subtypes of 
breast cancer      
Ductal carcinoma 
     
Breast cancer cases/non-
cases 
816/21005 282/8540 585/17154 303/8740 547/16906 
Age adjusted model 1.00 0.89 (0.79, 1.01) 0.90 (0.82, 1.00) 0.92 (0.81, 1.05) 0.89 (0.80, 0.98) 
Multivariable adjusted 
model 
1.00 0.89 (0.77, 1.02) 0.92 (0.82, 1.03) 0.96 (0.84, 1.10) 0.93 (0.83, 1.05) 
Lobular carcinoma 
     
Breast cancer cases/non-
cases 
122/21015 42/8542 92/17163 57/8743 81/16912 









1.00 0.89 (0.62, 1.27) 0.95 (0.72, 1.25) 1.18 (0.85, 1.63) 0.95 (0.67, 1.23) 
Mixed ductal/lobular 
carcinoma      
Breast cancer cases/non-
cases 
189/21015 68/8542 119/17163 54/8743 109/16912 
Age adjusted model 1.00 0.88 (0.68, 1.15) 0.80 (0.64, 0.99) 0.71 (0.53, 0.95) 0.75 (0.60, 0.94) 
Multivariable adjusted 
model 
1.00 0.95 (0.72, 1.25) 0.84 (0.66, 1.06) 0.78 (0.57, 1.06) 0.86 (0.67, 1.11) 
 
*Statistically significant multivariable-adjusted HR;
 a
HR=hazard ratio, CI=confidence interval; 
b
cases/non-cases in the multivariable models 
c
all 
models were adjusted for age, race/ethnicity, education, smoking status, physical activity, body mass index, NSAID use,  category and duration of 




LONGITUDINAL CHANGES IN DII AND RISK OF CANCER: A 
DISCUSSION OF STUDY RESULTS 
7.1 Summary of results 
Our hypothesis for this dissertation was that the inflammatory potential of diet 
changes over time and that long-term pro-inflammatory diets or shorter-term changes 
towards pro-inflammatory diets increase risk of colorectal cancer and of breast cancer. 
Using data from both the WHI OS and DMT, we first described changes over time in the 
inflammatory potential of diet using the DII, and showed that the DII score in the OS 
remained relatively stable from baseline to Year 3, while the DII decreased substantially 
from baseline to Year 1 in the DMT intervention arm, achieving the lowest mean score in 
Year 3, and then increasing gradually until study end while still remaining lower than 
baseline throughout the study period. The longitudinal trend of changes in DII was 
similar in both arms of the DMT; however, changes in the intervention arm were almost 
double those observed in the control arm during the first five years of follow-up. In both 
the OS and DMT, participants who experienced the largest DII decrease were more likely 
to have a normal BMI, a high educational level, and were A/PI or EA, while those who 
experienced the smallest decrease were more likely to be obese, had less than high school 
education, and were HP or AA. 
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Secondly, we demonstrated that: 1) a higher cumulative average score of the DII 
is associated with an increased risk of colorectal cancer especially colon cancer, while 2) 
a stable pro-inflammatory diet over a 3-year period increases the risk of rectal cancer. We 
found no substantial association between either cumulative average DII or shorter-term 
changes in DII and breast cancer, including molecular and histologic subtypes of breast 
cancer. To the best of our knowledge, this is the first study to characterize longitudinal 
changes in the inflammatory potential of diet and the association between the cumulative 
history, and changes over time in the inflammatory potential of diet, and risk of colorectal 
cancer or breast cancer.  
7.2  Potential mechanisms of action 
The link between inflammation and colorectal cancer is supported by findings 
from several studies showing either a reduced risk of colorectal cancer with regular use of 
NSAIDs,
83,84
 or a positive association between higher concentrations of inflammatory 
biomarkers and colorectal cancer risk.
89,113
 Other potential mechanisms through which a 
pro-inflammatory diet may increase risk of colorectal cancer include components of the 
metabolic syndrome, especially insulin resistance or glucose intolerance,
286-288
 and the 
microbiota. A high and sustained pro-inflammatory potential of the diet may compromise 
the host-microbiota mutualism favoring the proliferation of toxic bacteria that have been 
suggested to promote colon carcinogensis.
289
 For breast cancer, two potential 





 Generally, dietary patterns have been 
shown to modulate inflammation,
48-50
 and inflammation exerts an important role in the 
carcinogenesis process,
10,300
 but our findings imply that inflammation may not be a 
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substantial mechanism through which diet may influence breast cancer risk. Obesity, a 
state of low-grade chronic inflammation
229,230
 and a risk factor for breast cancer in 
postmenopausal women,
301
 has been suggested to increase breast cancer risk mainly 
through the hormonal pathway, with increased exposure to endogenous estrogen from 
adipose tissue.
302,303
 Indeed, though concentrations of inflammatory markers have been 
found to be higher in obese than normal weight women,
304
 a meta-analysis of prospective 
studies did not find an association between inflammatory biomarkers and breast cancer 
risk,
305
 further indicating that inflammation may not play an important role in breast 
cancer development. 
7.3 Strengths and limitations 
Major strengths of this study are the use of a large, well-characterized cohort (the 
WHI) with adequate number of outcomes providing ample power to detect significant 
associations. The DMT had a relatively long follow-up duration with diet assessed 
annually in random subsamples of the study population. Also, the use of a novel dietary 
index to score diet quality based on inflammatory potential at multiple time points 
provides evidence that inflammation may be substantially linked to colorectal cancer but 
not to breast cancer risk. Other strengths include accounting for changes in the 
inflammatory potential of diet over time, good regional and racial/ethnic representation, 
and the central adjudication of colorectal cancer and breast cancer diagnoses.  
Limitations to our study included the following: FFQ data were not available in 
the OS after Year 3 and thus we were not able to compare dietary behavior change 
between the OS and DMT beyond the first three years of follow up. The decrease in 
dietary inflammatory potential over time may have been due to survey learning effects 
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rather than a real improvement in diet quality. In our DMT sample, not every participant 
had FFQ data at all 11 time points, which could have reduced the effect of survey 
learning as participants did not complete the FFQs every year. We assumed that the 
random 30% of DMT participants sampled from year 2 until study end was representative 
of the entire DMT study population, a plausible assumption since these random 
subsamples were used for intervention monitoring in the DMT. However, sample sizes 
from Year 8 to 10 were very small and may not be representative of the entire DMT 
population. WHI enrolled only postmenopausal women, so generalizability and 
interpretation of our results is restricted to this population; however, average DII scores 
in the WHI were comparable to other US populations that have been examined.
39,282
 
Other limitations include known measurement error in using an FFQ for the assessment 
of diet and its inflammatory potential over time, and potential residual or unmeasured 
confounding, though we adjusted for many potential confounders in the models.  
7.4   Public health implications 
This dissertation addressed an important priority area of cancer research that 
includes the role of dietary patterns in relation to risk of cancer. The study is highly 
innovative in that this is the first time that repeated measures of the DII are being used to 
evaluate the association between changes in the dietary inflammatory potential over time 
and cancer endpoints. Our findings suggest lowering the inflammatory potential of diet as 
a means for colon cancer, and potentially rectal cancer prevention in postmenopausal 
women, but we did not find enough evidence that this potential prevention strategy may 
apply to breast cancer. Nevertheless, striving towards a more anti-inflammatory diet may 
have other potential health benefits beyond cancer prevention. 
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Patients at risk of inflammation-related conditions such as osteoporosis, obesity, 
cardiovascular disease, and diabetes, may also be at risk of cancer.
51,52
 Therefore a 
reduction in the inflammatory potential of the diet among patients with these conditions 
may improve overall health and reduce their cancer risk. We found that changes in the 
DII over time in the DMT were significantly modified by BMI, education and 
race/ethnicity, therefore interventions to reduce the inflammatory potential of diet need to 
incorporate differences in these lifestyle and demographic variables, in their designs. The 
diagnosis of most of these chronic diseases may be also a teachable moment during 
which most patients undergo lifestyle changes including diet changes to improve their 
survival experience,
53,54
 therefore health professionals armed with the knowledge of 
changes in the inflammatory potential of diets may be able to impart sound nutritional 
guidance that improves the overall health of patients with inflammation-related chronic 
diseases.  
Our finding of a relatively stable dietary inflammatory potential in an 
observational setting could mean that diet assessment at any point in time in a ~10 year 
observational study of postmenopausal women could be equally useful in determining 
disease risk estimates. The same conclusion would not apply for dietary intervention 
studies where we demonstrated that diet quality with respect to its inflammatory potential 
improves significantly over time in women enrolled in a low-fat, high-fiber, high-
vegetable and fruit intervention. Therefore diet assessments at multiple time points in an 
intervention study may be necessary for a more valid association between dietary 
inflammatory potential and disease risk. Finally, our findings strengthen the evidence for 
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a new tool assessing the long term overall quality of diet and providing support for its use 
in other studies of diet and cancer. 
7.5   Suggestions for future research 
Future observational studies with multiple diet assessments beyond three years 
will be needed to make more adequate comparisons in dietary behavior change in an 
observational versus an interventional setting. Studies (both observational and 
interventional) with multiple diet assessments in which every participant is surveyed at 
all the time points of diet assessment may be expensive but necessary to avoid making 
assumptions that random subsamples of participants are representative of the entire study 
population. Finally, interventions to test reductions in the inflammatory potential of diet 
as a means for both colon and rectal cancer prevention are now warranted given findings 
in the current study.  
7.6 Conclusion 
In this large prospective study of postmenopausal women, the average DII was 
relatively stable in the OS from baseline to Year 3, but decreased significantly over time 
in a manner consistent with improved anti-inflammatory potential, achieving its lowest 
mean value at Year 3 in DMT intervention participants and, to a smaller extent, among 
control arm participants. In all three study groups, the extent of decrease was influenced 
by BMI, education, and race/ethnicity.  
A history of long-term pro-inflammatory diets as well as shorter-term stable pro-
inflammatory diets; increase the risk of colon cancer and possibly rectal cancer, but was 
not associated with breast cancer risk. Our findings suggest lowering the inflammatory 
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potential of diet as a means for the primary prevention of colon cancer, and potentially 
rectal cancer but not breast cancer or any of its subtypes in postmenopausal women.  
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